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ABSTRACT
Tulathromycin is an antimicrobial approved for use in the treatment and control of bovine
respiratory disease and treatment of swine respiratory disease in United States and
European Union. This macrolide is a unique drug which has an extraordinary capacity to
accumulate in lung tissue and shows distinctive pharmacokinetic features in animals.
The pulmonary pharmacokinetics of tulathromycin in mice and pigs were evaluated in
this dissertation. In mice, the pulmonary pharmacokinetics of tulathromycin was
evaluated in healthy animals and animals challenged with lipopolysaccharide of
Escherichia coli (LPS-Ec). A group of challenged animals were also rendered
neutropenic. In pigs, the pulmonary pharmacokinetics of tulathromycin was assessed in
healthy animals and animals challenged intra-tracheally with LPS-Ec. The pulmonary
pharmacokinetics of tulathromycin was assessed using lung tissue (middle and caudal
lobes), pulmonary and bronchial epithelial lining fluid (BELF) samples.
We introduce a novel technique for the assessment of the concentration vs. time profile
of tulathromycin in BELF. This technique is based in the use of fiberscopically guided
bronchial micro-sampling probes (BMSp). The BMSp were first evaluated in a pilot trial.
Then, the BMSp were used as sampling tool for harvesting BELF in a larger study. The
use of BMSp represents a cost effective technique. This technique can be introduced in
discovery and preclinical pharmacokinetics studies for screening of candidate drugs that
will be indicated for the treatment of respiratory conditions. This technique might
enhance the experimental design and maximize the experimental resources (number of
animals, time, and cost).
This dissertation expands the understanding about the distribution of tulathromycin into
the lungs. It evaluates the kinetics of tulathromycin in middle and caudal lobes and intraairways compartment from healthy and animals with an acute pulmonary inflammatory
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response. This work provides the first evidence of the pharmacokinetics of tulathromycin
in lung tissue administered to neutropenic, normopenic, and neutrophilic mice. Finally,
this dissertation introduces and evaluates an innovative technique for the study of
pulmonary pharmacokinetics of drugs in veterinary species.
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Chapter 1:

PHARMACOKINETICS, PHARMACODYNAMICS AND
CLINICAL APLICATIONS OF TULATHROMYCIN IN
VETERINARY MEDICINE

1

Introduction
Tulathromycin is indicated as both metaphylactic and therapeutic in cattle and
therapeutic in swine for respiratory conditions. Its antimicrobial efficacy has been addressed in
several studies in cattle, swine, horses, and goats. Studies with clinical applications available in
the literature are summarized in Table 1.1.
The withdrawal time periods in cattle and swine intended for human consumption are
relatively short when compared with other approved drugs for treatment of similar conditions.
According to the United States Food and Drug Administration (FDA), when tulathromycin is
used following label indications, treated animals must not be slaughtered within 18 (cattle) and 5
(swine) days after the last treatment administration (129)
Tulathromycin can be used safely according to label directions in a variety of species
(98). In cattle and swine, there was a local tissue reaction from the injection that resolved over
time (98). Studies of toxicity in bovine, swine and caprine revealed minor clinical and injection
site histopathologic changes that resolved over time (26, 98). Hyper-salivation, head sheaking
and pawing at the ground has also been reported at therapeutic doses (98). In foals, the use of
tulathromycin has been associated with self-limiting diarrhea; elevated temperature, and
swelling at the injection site (140).

Chemical structure
Tulathromycin is a semi-synthetic macrolide antimicrobial, consisting of a regioisomeric,
equilibrated mixture of a 13- membered ring azalide (10%) and a 15-membered ring azalide
(90%), (10, 87). Its chemical core is built of two sugar moieties attached to the macrolactone
ring (molecular weight of 806.08) (38). The drug molecule has 3 nitrogen/amine functional
groups representing the first member of a novel sub–class of macrolides known as triamilides
(71). Each amino group can be positively charged at the appropriate pH. All macrolides are
basic molecules with pKa higher than 7. The molecule of tulathromycin is more basic than other
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macrolides. Depending upon the basic amino group in the molecule, pKas range from 8.6 to 9.6.
The constant of dissociation of tulathromycin may favor the accumulation of the drug in acidic
environments such as in airways of pneumonic patients and alveolar epithelial lining fluid (13,
84, 85). Tulathromycin is approximately fifty times more soluble in hydrophilic than hydrophobic
media (readily soluble in water at pH 8.0 or below) (38).
.
Indications
Tulathromycin has been approved in the US for the treatment of bovine respiratory
disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus
somni (Haemophilus somnus)and Mycoplasma bovis, and for the control of respiratory disease
in cattle at high risk of developing BRD associated with Mannheimia haemolytica, Pasteurella
multocida, Histophilus somni (Haemophilus somnus) and Mycoplasma hyopneumoniae.
Infectious bovine keratoconjunctivitis associated with Moraxella bovis and interdigital
necrobacillosis associated with Fusobacterium necrophorum and Porphyromonas levii have
been included in the list of approved indications. The FDA approved label indications include
only beef and non-lactating dairy cattle. In swine, tulathromycin can be used effectively and
safely to treat respiratory condition associated with Actinobacillus pleuropneumoniae,
Pasteurella multocida, Bordetella bronchiseptica, and Haemophilus parasuis (100).

Mechanism of action
Tulathromycin is a potent protein synthesis inhibitor (38). Macrolides bind reversibly to
the peptidyl transferase region of the 23s ribosomal subunit (125, 146). A study measuring the
displacement of 14C-erythromycin from the ribosome by tulathromycin indicated that
tulathromycin shares a common binding site on the ribosome with erythromycin (100).
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Pharmacodynamics
Both the macrolide ring and sugar moieties account for the antimicrobial activity of the
drug (97). A remarkable feature of the chemical structure of tulathromycin is that the molecule is
highly positively charged (87). This electrostatic charge has been associated with a markedly
enhancement of the drug penetration into cells by displacing magnesium ions at the outer
lipopolysaccharide layer of gram negative bacteria (87).
Tulathromycin, like other macrolides, is considered a bacteriostatic agent when tested
against

Staphylococcus

aureus

and

Escherichia

coli

(100).

However,

tulathromycin

demonstrated that it is bactericidal against M. haemolytica, A. pleuropneumoniae and
Pasteurella multocida revealed that tulathromycin is bactericidal (at 4x and 8x MIC) for some
isolates (49, 87).
The bacteriostatic or bactericidal effect of an antimicrobial is dictated by the
microorganism involved in the infection and the concentration time profile of the drug at the site
of infection (33, 34, 79). Tulathromycin concentrates markedly in some compartments including
pulmonary epithelial lining fluid, macrophages and neutrophils (29, 118). In these
compartments, the distribution and accumulation occurs at different rates and extents (29).
For tulathromycin, some local conditions may impact the activity of the drug. The
antimicrobial activity of tulathromycin against Histophilus

somni and other fastidious

microorganisms is dependent on the pH and pCO2 of the surrounding environment (103). This
study reported that MIC values increased as the pH decreased and pCO2 increased. Similar
observations have been reported for erythromycin, azithromycin and clarithromycin (36). These
findings have not been observed in vivo nor shown to be consistent for other microorganisms.
This local biochemical changes might be relevant in clinical situations that include abscesses
and/or necrotic tissue and intracellular infections. Under this scenario, the pH might be lower
and the pCO2 higher than in plasma (110, 111). Two studies involving tulathromycin and
abscessing conditions suggested that in vitro findings may not be fully correlated to all the in
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vivo conditions and may warrant further in vivo research. Both studies assessed
microorganisms that are intracellular pathogens and were responsible for triggering the
formation of abscesses (138, 142). The first study reported an acceptable clinical response of
goats with caseous lymphadenitis abscesses caused by Corynebacterium pseudotuberculosis
when treated with tulathromycin (142). The other study was done in foals with lung abscesses
(138). In the latter, abscesses were resolved after 53 days of therapy (2.5mg/Kg/once a
week).The authors attributed the lung abscesses to Rhodococcus equi (R. equi) but in fact the
causal microorganism(s) of the lesions was not identified. Under in vitro conditions,
tulathromycin showed poor activity against R. equi (24), indicating that further research is
necessary in this area before recommending the use of tulathromycin for the treatment of R.
equi in foals.
As indicated earlier, tulathromycin concentrates largely in inflammatory cells, which does
not imply that all the intracellular drug is readily available and active (134). Some fraction of the
intracellular drug content may be bound to the membrane, cellular proteins or trapped in
intracellular organelles (23, 131). Macrolides and flouroquinolones exhibit intracellular
antimicrobial activity as indicated by their capacity to treat intracellular organisms located in
phagosomes (Brucella sp in macrophages) (65), cytosol (Listeria monocytogenes in
macrophages) (102), endosomes (Mycobacterium tuberculosis in macrophages) (101) and
phagolysosomes (Staphylococcus aureus in macrophages and neutrophils). Nevertheless,
changing intracellular conditions may also render the molecule not fully active (eg. intracellular
pH)(134).
The exact intracellular location of tulathromycin has not been reported. The acidic
environment of lysosomes and the constant of dissociation (pKa >8) of tulathromycin suggest
that the drug may tend to be trapped within lysosomes, as reported for other macrolides (91,
130). The intracellular unbound and the unionized fraction of tulathromycin was no reported.
Considering that the MIC of some microorganisms is inversely related to pH, it is possible to
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hypothesize that the intracellular antimicrobial activity of tulathromycin is limited. On the other
hand, the intracellular concentrations are higher than plasma concentrations (AUC0-360
cell:plasma ratio ~500) [17], which might overcome potential changes of MICs. There are many
unanswered questions and based on the evidence available, it is not possible to predict the
intracellular antimicrobial activity of tulathromycin.
The bactericidal action of macrolides has been described as time-dependent for
erythromycin and concentration dependent for clarithromycin and azithromycin (86). Studies in
vitro with Haemophilus somnus indicated that tulathromycin has a concentration dependent
bactericidal activity particularly in the presence of plasma (103). The AUC/MIC ratio has been
proposed as the PK/PD variable that best predicts the antimicrobial activity of tulathromycin
(38). However, clinical PK/PD breakpoints for tulathromycin have not been reported yet.
Microbiological breakpoints have been established for susceptibility testing of bovine and swine
respiratory pathogens. Microbiological breakpoints have been defined based on bacterial
isolates obtained from field studies conducted in 10 European countries and from library
collections (48).

Non antimicrobial effects
Macrolide antibiotics affect the immune system by multiple mechanisms including
recruitment of inflammatory cells (58, 76), secretion of pro-inflammatory cytokines (124) and
pro-apoptotic activities (25, 69, 70, 145).
Tulathromycin significantly increased leukocyte apoptosis and reduced levels of proinflammatory leukotriene B4 in M. haemolytica-challenged calves (39). In vitro, tulathromycin
induces apoptosis in bovine neutrophils in a time and concentration dependent manner when
evaluated at concentrations that may be aimed intracelullarly (50 µg/ml to 2 mg/ml). It was also
demonstrated in vivo that tulathromycin induces apoptosis of BAL fluid leukocytes 3 h after its
administration. Tulathromycin did not significantly alter bronchoalveolar neutrophil numbers at
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24 h of infection. The authors also reported that tulathromycin significantly reduced levels of
phosphorylated inhibitor kappa beta, nuclear factor kappa-light-chain-enhancer of activated B
cells, p65, and mRNA levels of pro-inflammatory interleukin-8 in lipopolysaccharide stimulated
bovine neutrophils (39). The clinical significance of all these findings may warrant further
research.

Pharmacokinetics
The pharmacokinetics of tulathromycin has been evaluated in multiple species including
cattle, pigs, goats and foals. This macrolide has unique pharmacokinetic features.
Pharmacokinetic parameters available in the literature for multiple species are summarized in
Table 1.2. Tulathromycin is characterized by a rapid rate of absorption and large systemic
availability (~90%) after i.m and s.c. administration. The oral administration had a lower
systemic availability (~ 50 %) (141). In plasma, it has a long terminal half-life, ranging across
species from 60 to 110 h (Table 1.2). In cattle, linear pharmacokinetics is observed with
subcutaneous doses ranging from 1.27 mg/kg BW to 5.0 mg/kg BW (98). No pharmacokinetic
differences have been observed in castrated male versus female calves (36). Tulathromycin is
eliminated by biliary and renal excretion (98). In cattle and pigs, one-half and two-thirds of the
dose, respectively, are eliminated in the feces (100). Most of the dose is eliminated as
unchanged drug (141). Protein binding studies indicated that the unbound fraction of
tulathromycin ranges from 0.53 to 0.68 (99).

Lung pharmacokinetics
Lung pharmacokinetic studies in cattle, pigs and horses revealed an extraordinary
capacity of tulathromycin for accumulate in lung tissue (10, 29, 89, 139, 147). The magnitude of
the local accumulation and long persistence of the drug in the target tissue (lung) results in a
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convenient treatment regimen (single administration) and positive clinical outcome rates for
respiratory conditions (29).
Unbound plasma concentration is commonly accepted as a surrogate of interstitial fluid
concentration. Interstitial fluid is considered the site where most extracellular bacteria are
located during infection. For lung infections, pulmonary epithelial lining fluid (PELF) might be
considered as a potential site of contamination/infection where interaction between drug and
microorganisms might take place (32, 35). Thus, concentration of drug at this level might be
truly relevant from a pharmacodynamics and pharmacokinetics (PK/PD) stand point. However,
the ELF at the bronchial level does not represent a “pure” interstitial fluid or a plasma dialysate
fluid (5, 17, 18, 28, 63, 106). This limits the value of plasma concentrations as surrogate for
interstitial lung tissue concentrations (33, 80).
Multiples techniques have been applied to study pulmonary drug distribution including,
mini-bronchial alveolar lavage, sputum, positron emission tomography and microdialysis (9, 59,
67, 72, 92, 102, 126, 127, 144). However, factors like cost and availability of the technique,
experimental design limitations, accuracy, precision and informative value of the results limit
their applicability in veterinary species (52, 77, 128). There is not a totally convenient technique
available to study the drug kinetics in intra-airways compartments (unbound, interstitial,
epithelial lining fluid and secretions) in all the veterinary species and scenarios (different animal
sizes, multiple sampling, etc.). Some techniques may be applicable for some species and
circumstances but not for all possible experimental conditions.
For most of the drugs, the study of their disposition in lung of veterinary species has
been accomplished using lung homogenate samples. Consistent with this, the lung
pharmacokinetic of tulathromycin has been mainly described by quantifying the drug in lung
homogenate samples. Recently, the pharmacokinetics of tulathromycin has also been described
in pulmonary epithelial lining fluid (PELF) from cattle (29, 140) and foals (29, 140).
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Lung homogenate
Tulathromycin distributes into lung and persists in lung tissue for a long period of time
after a single administration (Table 1.2). In pigs, lung tissue concentrations were 24-181 times
those in plasma over a period of 0-360 h (10), while similar results were reported in cattle (Table
1.2) (29, 88).
Blood flow is one of the most relevant factors dictating the organ kinetics of a drug like
tulathromycin. The blood flow in lung is not homogenous across the organ (19). This may affect
the distribution of the drug within the organ (109). Lung homogenate samples are representative
of the whole lung. Therefore this technique does not allow determining if the distribution of the
drug within the lung is heterogeneous, which might have some relevance in terms of
antimicrobial effect.
Multiple factors usually change during infection/inflammation processes which clearly
might impact on the local accumulation and concentration time profile of a drug (34, 79).
Reports about drug concentrations in pneumonic tissue are inconsistent. Apley and Upson
(1993) reported lower concentrations of danofloxacin in pneumonic craneo-ventral tissue than in
normal caudo-dorsal tissue from cattle (3). In contrast, higher concentrations of oxytetracycline
in pneumonic calves have been reported (1, 3). In the case of tulathromycin, the concentration
time profiles in healthy and diseased lungs from cattle have been reported (99). No
pharmacokinetic results are presented or statistical comparisons reported.
The potential impact of a pulmonary inflammatory response on the concentration time
profile of tulathromycin in lung tissue has not been evaluated yet. The assessment of the
concentration time profile of tulathromycin in lung tissue from animals facing a pulmonary
inflammatory response and estimation of pharmacokinetic parameters would provide an
important information about the drug accumulation in lung tissue.
Lung homogenate samples do not represent a homogeneous sample. Lung homogenate
samples are processed in such a way that measured concentrations represent a composite of
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intracellular, interstitial and blood concentrations from both the alveoli and intrapulmonary
airways. For most of the infections, concentrations in the interstitial fluid and PELF are of
primary interest. Consequently, tissue:plasma ratios lack antimicrobial effect predictive value for
these drugs and possible most others. As mentioned (vide supra), the pharmacokinetics of
tulathromycin in lung tissue from pigs was evaluated, using lung homogenate. The use of
additional techniques to sample the lungs and the assessment of the pharmacokinetics of the
drug in different lung compartments would expand the understanding of the drug accumulation
in lung tissue.

Pulmonary epithelial lining fluid (PELF)
PELF is the fluid that distributes continuously throughout the respiratory tract including
alveoli (82). The composition and function of the lining fluid is heterogeneous across the
respiratory tract and the alveoli (82, 112).
It is accepted that biophase drug kinetics and accumulation are the primary factors
controlling the antimicrobial response (34, 79). PELF is a potential site of bacterial
contamination and colonization and as well as a site of bacteria to drug interaction. Therefore,
the kinetics of the drug at the PELF may be relevant for the antimicrobial effect of a drug. The
pharmacokinetic of tulathromycin in PELF was reported samples in clinically healthy bovines.
Results indicates that tulathromycin rapidly distribute into the intra-airways compartment and
persists there during a long period of time (terminal half-life 330 h). Tulathromycin also
distributes extensively into PELF from where drug concentrations decrease at a very slow rate
(29). Table 1.2 shows the pharmacokinetic parameters obtained in this study. The
pharmacokinetics of tulathromycin in PELF from pigs has not been evaluated yet.
Pulmonary epithelial lining fluid is commonly harvested by broncho-alveolar lavage
(BAL). The volume of PELF harvested in the BALF is usually estimated using serum and BALF
urea as dilution factor (29). Therefore, the concentrations reported in PELF represent composite
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drug concentrations from the trachea, lower airways and alveolar epithelial lining fluid. Each
pulmonary compartment is physiologically different and structurally heterogeneous, which may
affect the distribution of the drug. Consequently, the true informative value of the concentration
of the drug in PELF harvested by BAL is limited and cannot be accurately linked to a particular
anatomical site in the lung. It is important to stress that the use of BAL to harvest PELF does not
allow for an evaluation of the relative concentrations of free versus bound drug. In addition, drug
concentrations in PELF may be biased due to potential contamination of the PELF with drug
released from cells of the BALF sample (60). This technique has practical limitations that affect
the experimental design. The use of BAL to harvest PELF for quantitation of drugs should not
be performed more than once per animal without a priori validation as it may confound the
results. This is due to the changes that the lavage generates in the intra-airways and the
inevitable residual fluid remaining in the airways following the procedure.

Bronchial epithelial lining fluid (BELF)
Bronchial epithelial lining fluid represents the bronchial surface liquid. There are not
studies describing the concentration time profile of tulathromycin in BELF. The uses of bronchial
micro-sampling (BMS) probes have been used experimentally in human settings and may
provide a valuable alternative for pigs.

Alveolar macrophages and bronchial alveolar lavage cells
Macrolide antimicrobials accumulate to a high extent in different cell types (9, 59, 67, 72,
92, 102, 126, 127, 144). An in vitro study demonstrated that tulathromycin accumulates in
neutrophils and blood macrophages from bovine and porcine (118).
The accumulation of tulathromycin in bronchoalveolar cells (BAC) was reported in foals
(140). The concentration of tulathromycin in BAC was evaluated 24 and 192 h following a single
drug administration and following the last dose administration at steady state plasma
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concentrations. Results after a single administration indicates that tulathromycin accumulates
over time and drug concentration in BAC is not in equilibrium with plasma concentrations
(0.20+/-0.08 and 0.30+/-0.17 µg/ml for BAC24h

and

BAC192h, respectively and 0.14+/-0.05 and

0.02+/-0.01 µg/ml for plasma 24h and plasma 192h, respectively). After multiple drug
administrations, the concentration of tulathromycin was higher than after a single drug
administration (about 7 and 4 times for BAC24h and BAC192h, respectively) (140). These findings
suggest that there was no saturation of the intracellular accumulation of the drug, after a single
administration. Paradoxically, the co-administration of rifampicin, a potential efflux transporter
blocker, was associated with lower accumulation of the drug in BAC cell (p<0.05) (140).
Cox et al. (2010) described the concentration time profile of tulathromycin in pulmonary
epithelial lining fluid cells (majority macrophages) from clinically healthy calves (29). This result
demonstrates a notable accumulation of the drug in the PELF cells. The accumulation profile
suggests that there were two different rates of intracellular accumulation. Initially, the
accumulation profile is characterized by a fast phase of intracellular accumulation that goes
from 0 to 11h post-dosing followed by a slower phase that is extended up to 72 h post-drug
administration. After the maximal intracellular concentration (72 h) the drug tend do decline
slowly over time (29).
It is important to highlight that most of the studies describing the drug concentration in
alveolar macrophages are based on multiple assumptions. These assumptions are not always
valid and may lead to misleading interpretations. The first assumption is that all the cells in the
BALF sample represent alveolar macrophages. In fact, different cell populations (epithelial cells,
alveolar epithelial cells, interstitial macrophages, lymphocytes, etc.) are usually harvested by
BALF.
Second, the intracellular concentration is usually estimated using a reference
intracellular volume reported in the literature rather than the actual intracellular volume of the
sample (11, 29, 44, 114, 140). The use of a theoretical value requires one to assume that; (i)
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the reference value is representative of intracellular volume of study samples, (ii) the
intracellular volume is constant across all the cells (iii) the contamination of the cell pellet (106
cells) by non-macrophages cells does not impact on the results and (iv) all the alveolar
macrophages obtained in the sample are structurally and functionally similar and with the same
capacity to accumulate drug (43, 120, 122).
To obtain a cell pellet with 100 % alveolar macrophages, cell populations in the cell
pellet of the BALF sample should be sorted. A pellet of cells obtained by centrifugation of the
BALF sample always has a proportion of cells different to alveolar macrophages. Thus, it might
not be accurate to express drug concentrations in alveolar macrophages when in fact the
samples do not represent a pure cell population.
It is true that it may be difficult to set parallel experiments in order to rule out all those
assumptions in the context of in vivo pharmacokinetic studies. Nevertheless, to assume that all
this factors are not relevant in a study sample may lead to misinterpretation of the results.
The intracellular drug activity and its potential clinical significance was addressed in the
pharmacodynamics section (vide supra).

Local penetration and accumulation mechanisms.
After drug administration, the drug distributes from the plasma to the intercellular
compartments, airways secretions, epithelial lining fluid and cells (epithelial cells, fibroblast,
alveolar macrophages, and bacteria, among others). The mechanism(s) implicated in the
accumulation of tulathromycin in lung have not been elucidated yet. Many studies were done
trying to unveil and explain the factors and mechanism (s) involved in the lung accumulation of
macrolides and other drugs (Table 1.3). Several factors could have unequal impact on the
penetration and accumulation of the drug at different levels of the airways and alveolar
compartment (Table 1.3).
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There is evidence that accumulation of macrolides in ELF and cells may be dependable
on members of the organic anion transporting protein (OATP) family and efflux transporters (16,
64, 66, 115-117, 123). There is limited information about the potential interaction of
tulathromycin, drug transporters and tissue accumulation. In a study done in horses,
tulathromycin had no affinity to efflux carriers ABCB1 and ABCC2. Likewise, this study could not
demonstrate a connection between transporters and the accumulation of tulathromycin in the
PELF (140). More research is warranted in this area.
One of the most recurring hypothesis, but still conflicting, is the role of inflammatory cells
in the extraordinary accumulation of macrolides in lung tissue (4, 6, 15, 40, 41, 46, 47, 73, 104,
133). As mentioned above, in vitro and in vivo studies demonstrate that tulathromycin
concentrates in both alveolar and blood macrophages, neutrophils and bronchoalveolar lavage
cells (29, 140). These results may explain, at least in part, the high concentrations of
tulathromycin in lung tissue (60). In contrast, it is highly improbable that neutrophils have a
relevant role in healthy animals since neutrophils do not represent, numerically, an important
cell population in a normal lung. The potential role of neutrophils in drug accumulation might
increase during the acute phase of inflammatory processes. During inflammation, there is an
increased sequestration of neutrophils in the pulmonary capillaries as well as, accumulation of
cells within the lung interstitial and in the bronchoalveolar space (20). The exposure of cells to
antigens may leads to the accumulation of drug-loaded cells in the site of infection (5, 40, 41,
46, 47, 57). The antigen-cell interaction may trigger a rapid release of intracellular drug after
migration toward the chemotactic foci (46, 133). Loaded cells can also phagocytose the
microorganism(s) exposing it to high intracellular drug concentrations (46, 133). Clinically, this
phenomenon could be relevant when treating neutropenic animals. If neutrophils are relevant to
the accumulation of the drug in tissue, a lower drug exposure may be expected when
neutropenic animals are treated. There is limited information regarding the impact of
neutropenia on the accumulation of macrolides in the lung. A reduced tissue AUC of
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azithromycin was reported in leucopenic mice (137). The potential role of neutrophils in the local
lung concentration of tulathromycin over time has not been evaluated yet.
The paucity of conclusive studies explaining the lung accumulation of the macrolides
may be based on (i) the complexity and number of processes that might affect drug
accumulation (Table 1.3), (ii) the temporal inter-relationship among them and (iii) the difficulty to
design and execute studies that provide conclusive information.
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Appendix

Caprine

Species

Indication
category

Objective of the study

Conclusions of the study

Ref

Treatment
efficacy

Table 1.1. Summary of key clinical studies

To compare the effectiveness of 3
treatment regimens for small ruminants
with caseous lymphadenitis. Group A;
draining and flushing the lesions and SC
administration of PPG. Group B intralesional TUL, Group C TUL SC.

Proportions of lesions that had resolution of infection
by 1 month after treatment did not differ significantly
among the treatment groups

(142)

Cost effectiveness
and metaphylaxis

Bovine

To compare the efficacy and costeffectiveness of TIL vs. TUL as a
metaphylactic antimicrobial in feedlot
calves at moderate risk for BRD
The purpose of this study was to compare
the efficacy and cost-effectiveness of FLR
vs. TUL for initial treatment of UF in fallplaced steer calves that received
metaphylactic TIL on arrival at the feedlot

The purpose of this study was to
determine the efficacy and costeffectiveness of TUL vs. TIL or TET as a
metaphylactic antimicrobial in feedlot
calves

Calves TUL had lower initial BRD treatment rates
compared with TIL calves (p ≤ 0.05). There were no
significant differences in the BRD relapse rate, railer
rate, total mortality rate, mortality rate, ADG, and dry
matter conversion between the two groups. TUL was
less cost effective
No significant differences were observed in UF
relapses or the crude case fatality rate. Calves treated
with FLR had a lower case fatality rate (p= 0.04) for
BRD and Histophilus disease than did calves treated
with TUL. FLR was more cost-effective
Calves that received TUL had significantly lower initial
UF treatment and relapse rates; lower overall
chronicity, overall mortality, and cause-specific
mortality rates; higher ADG; and improved quality
grades. However, calves that received TUL also had
poorer (p<0.05) yield grades compared with calves that
received TIL or TET and worse feed conversion
compared with calves that received TIL. TUL was more
cost-effective

(136)

(135)

(14)
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Table 1.1. Continued
Indication
category

Metaphylaxis
Treatment efficacy

Bovine

Cost
effectiveness

Species

Objective of the study

Conclusions of the study

Ref

The purpose of this study was to
compare the relative cost-effectiveness of
FLR with that of TUL for treatment of UF
in feedlot calves at ultra-high risk of
developing UF that receive metaphylactic
TUL on arrival at the feedlot
Clinical effectiveness of TUL vs. TIL and
saline for the control of respiratory
disease in cattle at high risk for
developing BRD
To evaluate the efficacy of TUL
compared with TIL and FLR for the BRD
at high risk of developing BRD
To compare health and feed performance
parameters of beef stocker calves at risk
for bovine respiratory disease after
metaphylactic administration of TUL or
TIL

Calves that received therapeutic FLR had lower overall
mortality (P 0.45) and BRD mortality (P=0.05)
compared with calves that received therapeutic TUL,
but no significant differences were detected in feedlot
performance, carcass characteristics, or other animal
health variables. FLR was more cost-effective

(96)

TUL was significantly more effective in reducing BRD
morbidity when compared to the other groups

(61)

TUL demonstrated superior efficacy compared with TIL
and FLR

(107)

To evaluate the efficacy of TUL in the
treatment in commingled cattle with
clinical BRD treated with TUL or FLR and
prevention healthy animals in-contact
cattle treated with TUL, TIL or saline
To evaluate the clinical efficacy of a
single injection of TUL, compared with
saline solution-treated control calves, for
treatment of induced infectious bovine
KC in calves

Animals treated with metaphylactic TUL displayed
significant improvement in morbidity, mortality, firsttreatment success rates, improved ADG and feed:gain
ratio compared with TIL(p<0.05). Calves TUL were
healthier through the growing phase compared with TIL.
Similar percentages of animals showed sustained
clinical improvement at day 14 (TUL 83.3% vs. FLR
81.0%) and had not relapsed by day 60 (TUL 63.3% vs.
FLR 58.4%). Significantly more TUL-treated cattle
remained healthy to day 14 (92.4%) than TIL-treated
(83.7%) or saline-treated (63.7%) cattle, and this was
maintained through day 60 (TUL 85.4% versus TIL
75.1% and saline 56.2%)
A single dose of TUL was an effective treatment of
calves with experimentally induced infectious bovine KC

(83)

(51)

(68)
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Table 1.1. Continued
Indication
category

Treatment Efficacy

Bovine

Species

Objective of the study

Conclusions of the study

The objective of this study was to evaluate the
comparative efficacy of TUL vs. TIL at resolving
BRD in North American feedlot cattle

TUL was associated with an approximately
50% reduction in the risk of re-treatment for
BRD compared with treatment with TIL

To evaluate the efficacy of three antimicrobial
regimens CCFA followed by TUL 8 days later
(Group 1) or a one-course regiment of CCFA
(Group 2) or TIL (Group 3) as metaphylactic
To evaluate the efficacy of TUL or ENR for initial
treatment of naturally occurring BRD in feeder
calves
Comparative efficacy of TUL, TIL, and FLR in the
treatment of BRD in stocker cattle
Therapeutic efficacy of TUL and TIL against BRD
in feeder calves
To evaluate the efficacy of TUL in the treatment of
BRD associated with induced Mycoplasma bovis
infections in young dairy calves

Morbidity was significantly lower in Group 1
than in Group 2 and Group 3
TUL resulted in significantly higher therapeutic
success than did ENR. Animals treated with
TUL also had higher weight gains compared
with ENR
TUL proved to be significantly more effective
than either FLR or TIL in the treatment of BRD
TUL administered as a single-dose treatment
was efficacious in the treatment of
undifferentiated BRD
Compared
with
saline,
BRD-related
withdrawals, peak rectal temperatures, and
lung lesion scores were significantly lower for
TUL-treated calves than saline

Ref

(143)

(121)

(105)

(90)
(62)

(50)
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Table 1.1. Continued
Indication
category

Objective of the study

To evaluate the relative efficacy of TUL
vs. FLR for the treatment of UF in feedlot
calves in Nebraska

Bovine
Treatment Efficacy

Species

Comparative efficacy of TUL vs. FLR and
TIL against undifferentiated bovine
respiratory disease in feedlot cattle
Evaluate the efficacy of TUL in
interdigital necrobacillosis associated
with Fusobacterium necrophorum and
Porphyromonas levii in beef and nonlactating dairy cattle

Conclusions of the study
The first UF relapse, overall mortality and BRD mortality
rates in the TUL group were significantly lower than in
the FLR group. A higher proportion of carcasses in the
TUL group graded yield grade USDA-4 as compared
with the FLR group. There were no significant
differences between the TUL and FLR groups for the
other animal health variables measured, in ADG, the
overall distributions of quality grade and yield grade.
TUL was more cost-effective
TUL was more efficacious in the treatment of
undifferentiated BRD compared with FLR and, in one
study, compared with TIL

Ref

(113)

(119)

The percentage of animals classified as a treatment
success was significantly higher (p < 0.0001) in the TUL
treated group (30/50, 60%) compared to the control
group (4/50, 8%)

(99)

To evaluate the effectiveness of TIL
versus TUL for treatment of clinical
vesiculitis in bulls

The recovery rate was higher for bulls treated with TUL
(22/25=88%) than for TIL (11/23=48%) and both
antibiotics resulted in a higher recovery rates than
occurred the untreated control group (0/17; p<0.01)

(108)

This study demonstrated the ability of the
antimicrobials TUL and ceftiofur to clear
the spirochete Leptospira borgpetersenii
serovar hardjo type hardjo-bovis (L.
hardjo-bovis)
from
experimentally
infected cattle

TUL resulted higher rate of clearance of L. hardjo-bovis
organisms from the urine and kidney tissue than
ceftiofur and control animals

(27)
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Objective of the study

Conclusions of the study

Ref

Treatment
Efficacy

Evaluation of TUL in the treatment
of pulmonary abscesses in foals

TUL was well tolerated and appears promising for the
treatment of pulmonary abscesses in foals.

(138)

To evaluate TUL vs. ENR and
saline in the treatment of
pneumonia
in
weaned
pigs
inoculated
intra-nasally
with
Mycoplasma hyopneumoniae

Weight gain was significantly greater for TUL-treated pigs vs.
saline and ENR. Compared with saline. Compared with ENR,
there were no significant differences in proportional lung
weight or weight gains, but coughing and lung lesion scores
were greater for TUL-treated pigs (p < 0.05)
For all the treatments there were significative reductions in
mean rectal temperature and the severity of abnormal clinical
signs on days 2 and 10 compared with day 0. There were no
significant differences (p > 0.05) between treatments in
average daily weight gain. Tulathromycin was found to be
safe and highly effective in the treatment of natural outbreaks
of SRD.
The overall cure rate was 46.4% for saline-treated pigs,
71.1% for tulathromycin-treated pigs, and 63.1% for ceftiofurtreated pigs. The cure rate for tulathromycin-treated pigs was
significantly higher than for saline-treated pigs (p = 0.0116).
The mortality rate was significantly lower for both the
tulathromycin- and ceftiofur-treated pigs compared with those
treated with saline (p = 0.0148 and p =0.0195, respectively).

Treatment
Efficacy

Indication
category

Porcine

Species
Equine

Table 1.1. Continued

Evaluation of the clinical efficacy of
TUL vs. TIA and FLR in the
treatment of natural outbreaks of
SRD

Efficacy of TUL vs. ceftiofur and
saline injectable solution for the
treatment of naturally occurring
SRD

(75)

(81)

(90)
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Table 1.1. Continued
Indication
category

Treatment
Efficacy

Porcine

Species

Objective of the study

Conclusions of the study

Ref

Efficacy of TUL vs. ceftiofur in the
treatment SRD caused by
Actinobacillus pleuropneumoniae

The LSM bodyweight gains of the pigs treated with the TUL
and ceftiofur were significantly higher than that of the salinetreated group, and the LSM % of the total lung involvement
and incidence of respiratory disease associated with A.
pleuropneumoniae were significantly lower, but there were no
significant differences between the three groups of pigs
treated with TUL and ceftiofur

(54)

There were no significant differences between the numbers of
PCR-positive animals in the treated vs. control groups on any
of the sampling dates

(2)

There were no significant differences between the numbers of
PCR-positive animals in the treated vs. control groups on any
of the sampling dates

(2)

There were no significant differences between the numbers of
PCR-positive animals in the treated vs. control groups on any
of the sampling dates

(2)

To evaluate the effect of a single or
double dose of TUL vs. no treated in
pigs carrying Actinobacillus
pleuropneumoniae serotype 2 in
their tonsils
To evaluate the effect of a single or
double dose of TUL vs. no treated in
pigs carrying Actinobacillus
pleuropneumoniae serotype 2 in
their tonsils
To evaluate the effect of a single or
double dose of TUL vs. no treated in
pigs carrying Actinobacillus
pleuropneumoniae serotype 2 in
their tonsils
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Tlast
(h)

AUClast(hr*
ng/mL or
hr*ng/g)

AUCINF
(hr*ng/mL
or
hr*ng/g)

Vss
(L/Kg)

Vz_F_obs

Cl
(mL/kg*hr)

MRT
(h)

17,900
± 1,700

18,700
± 1,800

-

-

-

-

4,100
(3320–
5060)

360

903,600
(666000
–
123000
0)

1,230,0
00
(846000
–
182000
0)

-

-

-

-

-

-

360

13,700
± 1,000

14,100
± 1,200

11
±2

-

178
± 14

65
±9

2
±4

590 ±
170

360

13,000
± 3,000

14,000
± 3,000

-

-

-

-

-

-

-

-

-

-

-

36

90

0.007
± 0.001

1.8
±3

184
(158–
220)

0.0037
7
(0.0043
–
0.0031)

24

77

0.009
± 0.003

6

3

Reference

Cmax
(ng/mL)

Holstein male
calves2

Plasma&

360

Tmax
(h)

LT

500
± 400

Kel
(1/h)

Plasma

Terminal
half-life
(h)

Matrix

n

Beef
calves

Species

Table 1.2. Pharmacokinetics parameters (mean ± SD) of tulathromycin in multiple matrixes from cattle, pigs, horses, and goats

(88)

Plasma

4

87

0.0080
±
0.0011

LT

3

279

-

72

4510

360

867

-

Plasma

24

64

-

3

277

360

9.26

-

PELF

3

330

-

11

3730

360

492

-

-

-

-

-

PELF
cells

3

270

-

72

19500

360

5230

-

-

-

-

-

(29)

38

675
±174

192

-

-

-

-

-

58.6
± 4.3

(140)

6

59.1
± 7.6

0.012
± 0.002

-

987.8
± 226.9

360

-

10580
± 2743

-

26.6
±16.4

250.3
±
67.9#

70.6
± 3.0

(26)

5

60.9
± 8.9

0.011
± 0.001

-

1185
± 481.8

360

-

7918
± 1594

-

28.8
± 7.1

328.0
±
68.1#

68.3
± 7.1

(26)

10

110
± 19.9

-

0.4
±
0.26

633
± 300

-

12500
± 2020

-

32.6
±
6.09

0.208
±
0.37#

80.8
± 20

(147)

(at steady state)
6 W old
6 Mo old
5-7 Mo old

2-3 Mo old

Boer
goats1
Boer
goats1

Plasma

Plasma

Cmax
(ng/mL)

-

-

-

600

Vz_F_obs

Tmax
(h)

-

Tlast
(h)

Kel
(1/h)

192

Reference

0.36
±
0.11

464
± 178

MRT
(h)

-

-

2.47
±
4.09

Cl
(mL/kg*hr)

140
± 51

Plasma

Horses1

Vss (L/Kg)

10

Plasma

Boer
goats1

AUCINF
(hr*ng/mL
or hr*ng/g)

Terminal
half-life (h)

10

AUClast(hr*
ng/mL or
hr*ng/g)

n

Plasma

105
± 25

Matrix

2-3 Mo old

Horses1

Species

Table 1.2. Continued

-

89.1
±
22.8

(140)

39

2-3 Mo old

Pigs1

Plasma

&

6

Plasma

6

LT

6

142

Tlast
(h)

AUClast(hr*
ng/mL or
hr*ng/g)

AUCINF
(hr*ng/mL
or
hr*ng/g)

Vss
(L/Kg)

Vz_F_obs

Cl
(mL/kg*hr)

MRT
(h)

0.009
± 0.001

0.25

637
± 207

360

15200 ±
3160

15600
± 3150

-

-

-

-

0.010 ±
0.001

-

-

360

13700 ±
1860

0.007 ±
0.003

0.5

868 ±
350

360

12200 ±
3880

-

24

3470
(2740–
4400)+

360

615000

14000
± 1880

13.2
±
1.86

12600
± 3710

-

-

749,000

181
±
25.5

73.6
±
12.4

-

-

-

-

-

-

Reference

Cmax
(ng/mL)

75.6
±
13.7
67.5
±
13.5
91.0
±
38.9

Tmax
(h)

6

Kel
(1/h)

Plasma

Terminal
half-life
(h)

Matrix

n

Species

Table 1.2. Continued

(10)

2 Mo old

Pigs

0.0093
44.6
64.3
78.8
5.43 ±
4.19 ±
4.67 ±
580 ±
±
0.080
216
±
±
±
2.71
1.43
1.58
170
0.0017
18.3
21.2
16.7
(141)
78.7
0.0089
3.75
0.200
±
1.93
±
2.30
±
130
±
1140
104
±
8
±
±
±
216
PlasmaϮ
0.05
0.50
0.540
32.3 ± 280
8.61
6.75
0.0008
0.71
Dose regimen: Bovine and goats 2.5mg/kg subcutaneously. Pigs and foals 2.5mg/kg intramuscularly (& Intravenous administration
Plasma&

8

76.5
± 3.4

oral administration). LT: lung tissue homogenate. PELF: Pulmonary epithelial lining fluid; mean. 1: mean ± SD; 2: PK parameters
based on least squared means; # Cl/F (mL/kg*hr), +:values within parenthesis correspond to 99% confidence Interval.
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Table 1.3. Factors that may influence on the concentration time profile of the drug in lung tissue
Factors that might influence the penetration of the drug into lung tissue
(i) Epithelial permeability and absorptive capacity1,2
a. the tightness of cell junctions decrease from a maximum in the trachea to a
minimum in the distal airways before returning to a high value in the alveoli)
b. permeability of barriers might change during inflammation
(i) Organic anion transporting protein family and efflux transporters3, 4, 5, 6, 7,
(ii) Differential histological features8,9
a. the respiratory epithelium become gradually thinner with the number of
bifurcations
(iii) Tissue directed PK8,9,10,11,12,13,14,15, 16, 17, 18
a. kinetics of inflammatory cells
b. cell type13, 19,
c. cell status (eg. activated vs. inactive)
d. type of chemotactic stimulus
(iv) Differences and or changes of the surface area/tissue volume21,
a. a low SA/V reduces the velocity of penetration (airways vs. alveoli)
(v) Drug features22
a. molecular weight
b. plasma ionized vs. no ionized fraction
c. liposolubility
(vi) Intrapulmonary blood and lymph flow differences22, 23
a. the alveolar region receives the entire cardiac output by the pulmonary
circulation. Contrary, the airways receive approximately 1% of the cardiac
output24, 25
b. intrapulmonary changes in blood and lymph flow due to disease
c. surface areas and volume might change during infection lung
Factors that might influence the removal of the drug from lung tissue
(i) Retention of the drug in the mucus blanket over the ciliated epithelium of the airway
(ii) Drug features22
a. molecular weight26
b. tissue ionized vs. no ionized fraction
(iii) Extracellular tissue binding
a. fibrin32
b. debris32, 33
(vii) Cellular uptake (immune, epithelial, and/or fibroblast cells)13,14,15,16,17,18,34
(iv) Binding to phospholipids35
(v) Intrapulmonary metabolism36
(vi) Amount of respiratory secretions
Factors that might influence excretion and intra-airways distribution
(i) Mechanical excretion
a. Cough and sputum excretion37
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Table 1.3. Continued
Factors that might influence excretion and intra-airways distribution
b. metachronous beating of cilia (faster beating of the cilia in the trachea than in the
small airways) (impaired vs. increased ciliary function)26, 27
(ii) type of inflammatory response (chronic vs. acute)12, 31
(iii) type of drug physicochemical features22
1 (17); 2 (95); 3 (16), 4 (66), 5 (115), 6 (116), 7 (140), 8 (5), 9 (57), 10 (46), 11 (47), 12 (133), 13 (40), 14 (104),15 (41), 16 (73), 17
(6), 18 (15), 19 (12), 20 (37), 21 (7), 22 (109), 23 (93), 24 (30), 25 (42), 26 (55), 27 (132), 28 (56), 28 (22), 30 (94), 31(45), 32 (8), 33
(21), 34 (74), 35 (78), 36 (31), 37 (53)
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Chapter 2:

PHARMACOKINETICS OF TULATHROMYCIN IN HEALTHY
AND NEUTROPENIC MICE CHALLENGED INTRA-NASALLY
WITH LIPOPOLYSACCHARIDE FROM ESCHERICHIA COLI

43

Abstract
Tulathromycin is a macrolide approved to treat bovine and swine respiratory disease. In this
species, tulathromycin shows unique pharmacokinetic features including a remarkable
accumulation in lung tissue. The objectives of the present study were to assess the
concentration vs. time profile of tulathromycin at two different dose levels in mice and to assess
the plasma and lung tissue pharmacokinetics of tulathromycin in healthy and neutropenic mice
challenged intra-nasally with lipopolysaccharide from Escherichia coli 0111:B4 (LPS-Ec).
BALB/c mice were randomly allocated to four groups of 40 mice each: T-28, T-7, T7-LPS, and
T7-LPS-CP. Mice in T-28 were treated with tulathromycin at 28 mg/kg S.C (time 0 h). The rest
of the mice were treated with tulathromycin at 7 mg/kg S.C (time 0 h). Animals in dose group T7-LPS and T7-LPS-CP received a single dose of LPS-Ec intra-nasally at -7 h. Mice in group T7LPS-CP were also rendered neutropenic with cyclophosphamide (150 mg/Kg/intra-peritoneal)
prior to the administration of tulathromycin. Blood and lung tissue samples were obtained from 5
mice from each dose group at each sampling time over 144 h post-tulathromycin administration.
There were not statistical differences in lung tissue concentrations among T-7, T-7-LPS and T7LPS-CP. In lung tissue, the AUC0-144 of tulathromycin was 246000 h*ng/mL for group T-7, and
199000 h*ng/mL for both T7-LPS, and T7-LPS-CP. The lung to plasma AUC0-144 ratios were
7.95, 3.79 and 2.26 h for groups T-7, T7-LPS and T7-LPS-CP, respectively. The terminal halflife in lung was 82.5, 213 and 144 h for groups T-7, T7-LPS and T7-LPS-CP, respectively.
In all dose groups, the distribution of tulathromycin into the lungs was rapid and persisted at
relatively high levels during 6 days post-administration. The concentration vs. time profile of
tulathromycin in lung tissue was not influenced by the intra-nasal administration of LPS-Ec.
Results suggest that neutrophils may not have a positive influence on tulathromycin
accumulation in lung tissue when the drug is administered during either a neutrophilic or
neutropenic state.
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Introduction
Tulathromycin is a semisynthetic,

15-membered ring

macrolide derivative of

erythromycin. It represents the first member of a novel sub-class of macrolides known as
triamilide (28). This macrolide shows outstanding metaphylactic and therapeutic efficacy in
bovine and swine respiratory disease after a single S.C. administration (1, 5, 7, 20, 22, 26, 31,
33, 37, 41, 49, 54, 55). Tulathromycin has also been approved by the United States Food and
Drug Administration (FDA) to treat infectious keratoconjunctivitis caused by Moraxella bovis and
bovine

inter-digital

necrobacillosis

associated

with

Fusobacterium

necrophorum

and

Porphyromonas levii (39).
Tulathromycin has unique pharmacokinetic features. It is characterized by a rapid rate of
absorption and a large volume of distribution (Vdss13.2 L/kg in pigs and 33 L/kg in goats) (5, 58).
Pharmacokinetic studies in cattle, swine, and foals revealed an extraordinary capacity of
tulathromycin to rapidly accumulate in lung tissue and persist for a long period of time (apparent
elimination half-life is about 6 days in pigs and cattle) (5, 35). In one study, the area under the
concentration-time curve in lung tissue homogenate to area under the plasma concentrationtime curve (AUC0-360) ratio reported was 94 and 181 for bovine and swine, respectively (5, 11),
and the pulmonary epithelial lining fluid apparent half-life was >100 h in Holstein calves (11).
These features would explain to some extent the excellent clinical outcome of tulathromycin
when it is used within the label frame.
The mechanism by which tulathromycin accumulates in lung tissue remains unknown.
As reported for other macrolides, tulathromycin is taken up by resident inflammatory cells
(alveolar macrophages) (11). Tulathromycin also accumulates in blood macrophages and
neutrophils (48). This might be relevant during the inflammatory process if tissue-directed
pharmacokinetics hold true for tulathromycin (3, 4, 8, 14, 15, 18, 19, 30, 40, 53). Increased
amounts of azithromycin and erythromycin in infected lungs have been reported (8, 17, 53). It
was suggested that the accumulation of azithromycin in tissues appears related to the rapid
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uptake and transport to the infection site by cells such as polymorphonuclear neutrophils,
monocytes, alveolar macrophages, and fibroblasts (18, 19). Also, a reduced tissue AUC of
azithromycin was seen in leucopenic mice (56). These results have been used to link neutrophil
migration and pharmacokinetics of macrolides.
Neutropenia is a common cellular blood shift that occurs during an acute inflammatory
process. Tulathromycin is indicated for both metaphylaxis and therapy of bacterial infections.
Consequently, drug administration may take place during a neutropenic state. Under this
scenario, our hypothesis is that the concentration vs. time profile of tulathromycin in lung tissue
is influenced by neutropenia and acute pulmonary inflammatory response.
The present study has two objectives: to assess the concentration vs. time profile of
tulathromycin at two different dose levels in mice and to assess the concentration time profile of
tulathromycin in the plasma and lung tissue in healthy and neutropenic mice challenged intranasally with lipopolysaccharide from Escherichia coli 0111:B4.

Material and methods
Animals and housing
Female BALB/c mice (n = 205) (17.4–22 g) were purchased from a local commercial
source. Drinking water was available ad-libitum throughout the study. Animals were
acclimatized for a minimum of 7 days prior to administration of the treatments. Dose calculations
were based on body weights determined previous to dosing. Before initiation of the study,
procedures involving the care or use of mice were reviewed and approved by the Pfizer Animal
Health Institutional Animal Care and Use Committee (IACUC).
Study design
Mice were randomly allocated to four dose groups of 40 mice each: T-7, T-28, T7-LPS,
and T7-LPS-CP (LPS, lipopolysaccharide; CP, cyclophosphamide). Within each dose group,
animals were allocated randomly to eight sampling times (from 30 min to 144 h) with five
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animals in each. All animals within a treatment group (n = 5) were kept in a single cage. In
addition, 45 mice were allocated into a control group. Animals within the control group were
assigned to one of three control groups: (i) CT-NT (no treatment), (ii) CT-LPS (intranasal
administration of LPS), and (iii) CT-CP (cyclophosphamide).
Treatment dose group T-7, T7-LPS, and T7-LPS-CP were administered one S.C.
injection of tulathromycin at 7 mg/kg in the inter-scapular space at time 0. The final
concentration of Draxxin was adjusted using the commercial formulation without tulathromycin
provided by Pfizer Animal Health. Animals in dose group T-28 were administered one S.C.
injection of tulathromycin (Draxxin Injectable Solution) at 28 mg/kg in the inter-scapular space at
time 0. Animals in dose group T-7-LPS and T7-LPS-CP received a single LPS (E. coli 0111:B4)
dose (30 µg of LPS diluted in 30 µL of sterile saline solution) at -7 h by intranasal administration
under general anesthesia as described below. Additionally, mice from group T7-LPS-CP were
treated with cyclophosphamide (Cytoxan cyclophosphamide for injection, USP, Bristol-Myers
Squibb Company, Princeton, NJ) at 150 mg/kg by intra-peritoneal (Figure 2.1) route at -4, -1,
and + 2 days (when applicable).
Animals within the control group (CT-NT, not treated with tulathromycin), received no
treatment. Mice in the CT-LPS group received an intranasal dose of LPS as described above.
Animals in the CT-LPS-CP were treated with two doses of cyclophosphamide at -4 and -1 days
before sampling time of these animals (day 0). Additionally, these animals were treated with
LPS at -7 h as described above.
Preparation of inoculum
Lipopolysaccharide from E. coli 0111:B4 (LPS-Ec) purified by phenol extraction was
purchased from Sigma Aldrich (lot number 118K4052) (Saint Louis, Missouri, USA). The LPSEc powder was re-suspended in saline solution (NaCl 0.9%) to obtain a final concentration of 1
µg/mL. The same inoculum size of LPS solution (30 µL) was used for all the LPS-Ec-treated
animals.
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Administration of inoculum
A single LPS dose was administered intra-nasally under general anesthesia (Figure
2.2.1 and 2.2.2). Mice were placed on their back on a solid surface with an inclination of 35
degrees. The LPS solution was gently dropped in one of the nostrils. After LPS administration,
mice were kept on the same inclined board until recovery from anesthesia. After recovery, mice
were placed back in their corresponding cages.

Sampling
Five mice from each dose group per sampling time were anesthetized to obtain blood
and lung tissue samples at 30 min, 1, 24, 48, 72, 96, 120 and 144 h post-tulathromycin
administration.
Mice in the control group were euthanized and lungs excised as following: CT-NT (n =
3) and CT-LPS at 7 h (n = 3) and 24 h (n = 3) post-LPS administration. In the group CT-LPSCP, lung tissue samples were taken at time 0 (7 h post LPS and after two doses of CP). Lungs
were filled with formalin 10% (0.7 mL) and placed individually in a container with formalin 10%
until histology evaluation. Also, blood samples were withdrawn from the CT-NT (n = 10), CTLPS (n = 7), and CT-LPS-CP (n = 7) groups at time 0 for white cell counts. White cell count was
performed using the automat cell counter (Advia® 120 hematology system, Deerfiel, IL, USA)
the rest of the animals and tissues were used for analytical purposes.
Plasma sampling
Blood samples were obtained by terminal cardiac puncture under general anesthesia.
Briefly, once mice were under an appropriate anesthetic level, animals were placed on their
back on a solid surface. The xiphoid process was palpated at the caudal aspect of the animal's
sternum. A 22-gauge needle attached to a 1 mL syringe was inserted toward the heart as
determined by palpating for the heartbeat. Immediately after blood samples were withdrawn,
animals were euthanized using an overdose of pentobarbital.
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Blood samples were placed into tubes with EDTA as an anticoagulant and kept in ice
until centrifugation. Blood samples were centrifuged for 15 min at 3000 RPMs at 5°C. Plasma
samples were placed into cryotubes and kept at -20°C until analysis.
Lung tissue sampling
Following euthanasia, lungs from each mouse were removed from the thorax cavity.
Lung tissue samples were placed into cryotubes and kept at -20 °C until analysis.

Wet-to-dry ratio determination
An approximate 0.5 cm x 0.5 cm subsection of lung tissue sampled for lung tissue
homogenate was taken for wet-to-dry ratio determination. Samples were placed in an aluminum
container and weighed. The wet weight was recorded. Then samples were dried in an oven at
60°C for 15 days. Samples were then weighed again for wet-to-dry ratio determination using the
following equation:
Wet-to-dry ratio = wet weight (g) / dry weight (g)
Anesthesia and euthanasia
Both LPS administration and sampling general anesthesia were performed with intraperitoneal administration of ketamine (100 mg/kg) combined with xylazine (10 mg/kg). All
experimental animals were euthanized after blood sampling and before recovery from
anesthesia using an overdose of pentobarbital.

Analytical methods
All the matrices samples were analyzed for tulathromycin content by a Waters Acquity
Ultra Performance Liquid Chromatography (UPLC) system with tandem mass spectrometry
detection (LC-MS/MS) (Waters Corp., Milford, Massachusetts, USA) following procedures
described (11, 16). Roxithromycin was used as internal standard (43).

50

Plasma

Plasma samples were diluted (1:100 and 1:50) with 50 mM K2HPO4. Samples (100 µl) were
spiked with 100 µL internal standard (roxithromycin 25 ng/mL). Solid phase extraction (SPE)
cartridges (Oasis MCX 1mL, Waters) were preconditioned with 1.0 mL of acetonitrile followed by
1.0 mL of pH 6.8 and 50 mM K2HPO4. A weak vacuum was applied to the SPE manifold. All
extracts were decanted onto the SPE cartridges. The SPE tubes were rinsed sequentially with
1.0 mL of pH 6.8, 50 mM K2HPO4, and 1.0 mL of H2O. Cartridges were loaded with quality
control, blank plasma, and test samples (200 μL). Analytes were eluted with 2 × 0.5 mL of
freshly prepared 5% NH4OH/95% acetonitrile into labeled 13- × 100-mm polypropylene tubes.
Collected extracts were evaporated to dryness under a stream of nitrogen at 50−55 °C. Extract
residues were reconstituted with 200 µL of 20 mM ammonium acetate (pH 4.0) by vortex mixing.
Reconstituted samples were transferred into autosampler vials. Chromatography was
accomplished with a BDS Hypersil C8 30 x 2.1 mm column (Thermo Fisher Scientific Inc.,
Waltham, MA) at a flow rate of 0.300 mL/min with a linear gradient chromatography. The mobile
phase initially consisting of 80% A (20 mM pH 4 ammonium acetate) and 20% B (acetonitrile)
and was changed to at 0.5 min of 20% A and 80% B. Retention times were approximately 1 min
for tulathromycin and 1.2 min for roxithromycin. The mass spectrometer (AB Sciex Linear Ion
Trap 4000 QTRAP equipped with a turbo spray ion source, Foster City, CA) was used in the
positive ion mode using an electrospray ionization source, and positive ions were monitored
with precursor → product ion pairs of 806 → 577 for tulathromycin and 837 → 679 for
roxithromycin. Prior to the analysis of the study samples the potential interaction of LPS and
cyclophosphamide was evaluated using quality control. There was no interference between
those substances with tulathromycin. Calibration curves were generated automatically using
Analyst 1.0 software (Perkin-Elmer).The calibration curve (R2>0.99) occurred over the range of
to 500 ng/mL using nine calibration standards (by duplicating each concentration), and five
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quality control samples (15.63, 62.5, 125, 250, 500 ng/mL) (by quadruplicating each
concentration level). Standard curve and quality controls were run at the beginning and the end
of the analytical run. The lower limit of quantification (LLOQ), defined as the standard
concentration where analysis of 3 replicate samples did not exceed a coefficient of variation of
20%. The LLOQ was 3.90. For the quality control samples, the intra-run coefficients of variation
ranged from 12.9 to 19.0%, and the intra-run biases ranged from -14.0% to 10.0%. For the
calibration curve samples, the intra-run coefficients of variation ranged from 2.0 to 19.7%, and
intra-run biases for these samples ranged from -10.6% to 8.38%. All the study samples were
analyzed in a single analytical run.

Lung tissue homogenate samples
Samples were processed as described previously by Galer et al. (2004) (16). Briefly, a
lung tissue sample (0.100 g) was homogenized with 0.050 mL of 50 mM phosphate buffer, pH
6, and 2.5 mL of 0.04 M phosphoric acid. The homogenate was centrifuged, and 0.25 mL of the
supernatant was then mixed with 0.25 mL of 50 mM pH 6 phosphate buffer and 0.25 mL of
internal standard solution, and the entire sample was loaded onto an Oasis MCX 1cc (30 mg)
SPE cartridge. The cartridge was washed with 1 mL of 50 mM pH 6 phosphate buffer, 1 mL of
distilled deionized water, and 1 mL of acetonitrile. The drug was then eluted from the cartridge
with two 0.5 mL volumes of 5% ammonium hydroxide/ 95% acetonitrile. After evaporation with
nitrogen gas at 50 °C, the sample was reconstituted with 0.95 mL of 20 mM pH 4 ammonium
acetate and acetonitrile (80:20 v:v). A 10 µL aliquot was then injected into the chromatographic
system. The calibration curve (R2 >0.99) occurred over the range of 3.90 to 1000 ng/g lung
tissue using 10 calibration standards, and three quality control samples of lung tissue (7.80,
125, and 1000 ng/g) were included in each analytical run. The lower limit of quantification
(LLOQ), defined as the standard concentration where analysis of 3 replicate samples did not
exceded a coefficient of variation of 20%. The LLOQ was 3.90. For the quality control samples,
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the intra-run coefficients of variation ranged from 4.9 to 8.1%, and the intra-run biases ranged
from -4.0% to 9.4%. For the calibration curve samples, the intra-run coefficients of variation
ranged from 1.85 to 8.1%, and the intra-run biases ranged from -7.5 % to 13.6%. All the study
samples were analyzed in a single analytical run.

Pharmacokinetic and biometrical analyses
Plasma and lung tissue homogenate drug concentrations were analyzed using an
ANOVA linear mixed model as implemented by the Statistical Analysis System (SAS, version
9.2, Cary, NC, 2011). A natural log transformation (ln) was applied to the concentration data for
both matrices prior to analysis. Least squared means (geometric mean) and 95% confidence
bounds were calculated with natural logarithm transformed data and the final results back
transformed representing geometric means (11). Standard errors of LS means were estimated
and 95% confidence interval (CI) was constructed. Back-transformed LS means and CIs for
each treatment and dose group were reported. Back transformed least squares mean (LS
mean) concentration was used as an estimate of treatment means. The dose groups were
tested for significant differences for fixed effects at the  = 0.05 level, indicating that p values 
0.05 showed a significant difference for the effect. The wet-to-dry ratio was summarized as
arithmetic means, standard deviations (SDs), and coefficient variations CVs.
Wet-to-dry ratios were compared statistically by the same linear mixed model. Linear
regression analysis was performed to test the linear association between wet-to-dry ratio and
raw drug concentration data.
Pharmacokinetic parameters were estimated based on the back-transformed LS means
(11). Pharmacokinetic parameters were estimated using WinNonlin software (Standard ed.,
version 5.1, Pharsight Corporation, Mountain View, CA, USA). The WinNonlin 200 model was
used for the non-compartmental analysis. The AUC through 144 h post-dose (AUC0-144), area
under the concentration-first moment time curve through 144 h post-dose (AUMC0-144), mean
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residence time (MRT), and the terminal elimination half-life (t1/2) were estimated. The AUC0-144
was calculated by the log-linear trapezoidal rule, and λz was estimated with uniform weighting.
The observed peak LS mean concentration (Cmax) and time of its occurrence (tmax) was obtained
from inspection of the back-transformed LS mean concentration.
Results
All experimental animals remained in good health throughout the acclimatization period.
One animal (#149) of dose group T-7-LPS-CP (72 h) was euthanized due to animal welfare
concerns. Animal 145 (48 h) from the same dose group was found dead. These animals were
not replaced. The rest of the experimental animals remained in good health throughout the
study period. No adverse reactions or detrimental health effects were observed following the
administration of tulathromycin. Animals in dose groups T-7, T-7-LPS, T-7-LPS-CP, and T-28
received an actual averaged dose of 6.95, 6.90, 6.99, and 27.57 mg tulathromycin/kg,
respectively. In one animal from dose group T-7 (animal 4); there was leakage of the treatment
solution from the administration site. Therefore this animal was considered under-dosed and
was excluded from the study.
Plasma
Tulathromycin was rapidly absorbed in both dose groups. The maximal LS mean
concentration of tulathromycin was observed 30 min after tulathromycin administration for dose
group T-7, T-28, and T-7-LPS and 1 h for T-7-LPS-CP. The Cmax LS mean (± SE) of
tulathromycin in plasma was 6790 ± 2450 (tmax 30 min) and 6920 ± 2520 ng/mL (tmax 1 h) in dose
groups T-7-LPS and T-LPS-CP, respectively. Plasma concentrations of tulathromycin results
are included in Table 2.1 and shown in Figures 2.3 and 2.4. The pharmacokinetic parameter
results are included in Table 2.3.
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Lung tissue homogenate
Tulathromycin rapidly and extensively distributed into lung tissue. Results are presented
in Table 2.2. In dose groups T-7 and T-28, the tulathromycin Cmax was 4410 and 27800 ng/g
(observed) at 30 min and 1 h post-tulathromycin, respectively (Figure 2.5). The Cmax in dose
groups T-7-LPS and T-7-LPS-CP was 3.93 and 5.49 ng/g occurring at 30 min and 1 h post-dose
tulathromycin, respectively (Figure 2.5). There were no statistically significant differences in
tissue concentrations among the two dose groups treated with 7 mg/kg of tulathromycin. At all
the sample times the lung tissue LS mean concentrations far exceeded the plasma
concentrations in the four treatment groups. In all the dose groups, tulathromycin persisted for a
long period of time with an MRT that ranged between 138 to 287 h. Summary of
pharmacokinetic parameters are presented in Table 2.3. The lung-to-plasma AUC0-144 ratio was
1.3 times higher in dose group T-7 than in group T-28 (AUC0-144 ratio 7.95 vs. 5.77,
respectively).
Wet-to-dry ratios for lung tissue
Wet and dry ratio weights were determined in all the dose groups. Summarized data are
presented in Table 2.4. There were statistically significant differences between dose group T7
vs. T-7-LPS (p<0.01) and T7 vs. T-7-LPS-CP (p<0.001) between 72 and 144 h. No significant
differences were observed between the T-7-LPS and T-7-LPS-CP dose groups (p > 0.05).
Likewise, there were no statistically significant differences among the three dose groups during
the first 48 h post-tulathromycin administration. There was a negative linear relationship
(p<0.01) between raw data concentration and the wet-to-dry ratio for the T-7-LPS and T7-LPSCP dose groups (Figure 2.6 and 2.7). However, the fraction of variation of the drug
concentration explained by the wet-to-dry ratio (72 to 144 h) was low (R2 <5%) for both dose
groups.
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Lung tissue histology
Neutrophil accumulations were observed in the lumen of bronchioles (minimal to mild),
interstitial around bronchioles (minimal to mild), in alveolar spaces (minimal), and in alveolar
septa (minimal to moderate) of animals treated with LPS alone (LPS–7 h and LPS – 24 h), but
not in non treated animals (CT-NT) nor in animals pre-treated with cyclophosphamide and then
treated with LPS.
White blood cell count
A white blood cell (WBC) count was performed in all control animals: CT-NT, CT-LPS,
and CT-LPS-CP. The WBC results are summarized in Table 2.5 and neutrophil count results
are presented graphically in Figure. 2.8.
Discussion
The concentration vs. time profile of tulathromycin in lung tissue homogenate and
plasma was evaluated in all dose groups. Also, pharmacokinetic parameters of tulathromycin
were estimated in both matrices.
In dose groups T-7 and T-28, tulathromycin was rapidly absorbed (Figure 2.4).
Tulathromycin was distributed extensively and rapidly into lung tissue in both of these dose
groups, as previously reported in other species (11, 35). Tulathromycin was slowly eliminated
from lung tissue of both dose groups T-7 and T-28 with an MRT of about ~6 days (Table 2. 3).
A similar pharmacokinetic trend in mice has been reported for other macrolides including
erythromycin, spiramycin, clarithromycin, and azithromycin (56). Furthermore, results suggest
that tulathromycin has a larger accumulation and persists in lung tissue longer than other
macrolides in mice (56). The high affinity of the drug for lung tissue and the long persistence of
tulathromycin was also reported in cattle (11, 35), pigs (5, 36), and foals (57). Multiple factors
have been hypothesized to explain the remarkable accumulation of macrolides in lung tissue,
including interactions with phospholipids, intracellular accumulation (bronchial and alveolar
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epithelium and bronchoalveolar cells) due to ion trapping, active transport (carriers such as
members of the organic anion transporting protein), and endocytosis (9, 11, 27, 32, 45-47, 50).
However, the identification and description of the mechanism(s) involved in tulathromycin lung
tissue accumulation still remains unknown.
Tulathromycin is a lipid-soluble triamilide (28). Therefore, the overall molecule contains
three basic functional groups with PKas ranging from 8.6 to 9.9. These features may favor the
penetration and intracellular accumulation of the drug in an acidic environment (ion trapping).
Further research is necessary to elucidate the mechanism(s) and factor(s) involved in the
intracellular accumulation of the drug.
We evaluated the pharmacokinetic profile of tulathromycin at two different dose levels in
order to predict drug concentrations for future studies. In plasma, the AUC0-144 ratio adjusted by
dose between dose groups T-7 and T-28 was 1.22. In lung tissue, the AUC0-144 ratio adjusted by
dose between dose groups T-7 and T-28 was 0.89 (mean actual doses 6.95 vs. 27.57 mg/kg,
respectively). The results obtained indicate that, at the two dose levels evaluated, the dose
response could be different in plasma and lung tissue. We cannot confirm dose proportionality
or lack thereof because the data is insufficient. It is important to stress that both parallel design
and destructive sampling are associated with increased imprecision of the data due to interindividual variability.
In this study, two experimental models were implemented. It was used an
experimentally-induced neutropenic mice and animals treated intra-tracheally with LPS-Ec.
Lipopolysaccharides are structural and functional components of the gram negative bacterial
outer membrane (10). The administration of LPS in the respiratory system has been extensively
used to trigger an acute inflammatory response (2). The administration of LPS in the respiratory
system prompts an acute infiltration of polymorphonuclear neutrophils and the release of a
myriad of inflammatory mediators (2, 13, 23, 25, 44, 52). The model implemented in the present
study has been fully described elsewhere (51). The neutropenic mouse model has been
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extensively used to unravel the pharmacokinetics and pharmacodynamics of antimicrobials (24,
29, 42).
In a pilot trial, we evaluated the accumulation of inflammatory cells in lung tissue from
mice treated intra-nasally with LPS and with and without cyclophosphamide. Administration of
LPS induced accumulation of neutrophils in the lung. In contrast, when cyclophosphamide was
included in the protocol, there was no neutrophilic accumulation (Villarino, et al. data
unpublished). In the present study, we evaluated the LPS response in lung tissue only in a
subset of control mice (untreated and treated with LPS and LPS plus CP). At the time of
tulathromycin administration, neutrophils were present to a moderate extent in the alveolar
septa. Mild congestion in capillaries was noted only in the mice treated with LPS. Neither
neutrophils nor any other change was observed in the control and CT-LPS-CP animals. We also
assessed the WBC in a control group at the time of tulathromycin administration. The
administration of LPS induced a remarkable change in the average blood cell count when
compared with control animals (control 6.19 ± 2.94 vs. LPS-treated 7.24 ± 1.64 x 103/µl) and
with reference values for anesthetized BALB/c mice (Table 2.5) (34).
The WBC count in the animals treated with LPS and CP was lower than in the other
groups (0.93 ± 0.27 x 103/µl). These changes were also reflected in the neutrophil count.
Previous studies considered animals neutropenic when the cell count was <100 cell/µl (12, 42).
In the present study, the mice were severely neutropenic regardless of the administration of
LPS (0.04 ± 0.01, 3.17 ± 1.02, and 0.69 ± 0.37 x 103/µl for the CT-LPS-CP, CT-LPS, and CT-NT
group, respectively) (2.5 and Figure 2.8) (34). Therefore, at the time of tulathromycin
administration, animals treated with LPS were neutrophilic (abnormally higher number of
neutrophils in blood) and exhibiting accumulation of neutrophils in lung. In contrast, mice treated
with LPS plus CP where neutropenic without recruitment of neutrophils into the lung.
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The AUC0-144 of tulathromycin in plasma of neutropenic mice was 1.7 and 2.8 times
higher than in healthy mice (T-7) for dose groups T-7-LPS and T-LPS-CP, respectively. The
reasons for this change in drug exposure are unknown.
In both LPS-treated groups, tulathromycin distributed extensively and rapidly into lung
tissue, as previously observed for group T-7. In the LPS-treated animals, there is a trend to
have lower AUC0-144 values than in non-LPS-treated (T-7) animals (Table 2.3). The reasons for
lower AUC0-144 values in LPS-treated animals are unclear. This trend was not compared
statistically because of the lack of dispersion parameters as a consequence of the destructive
sampling used in this study.
An increase of the wet-to-dry ratio 48 h post-LPS administration could be caused by the
edema associated with the inflammatory process. This could have a dilution effect on the drug
in lung tissue homogenate explaining the lower LS mean concentrations observed in LPStreated animals. However, the wet-to-dry ratio explained less than 5 % of the change in the lung
tissue drug concentration from LPS treated mice (Figure 2.6 and 2.7). Changes in the
pharmacokinetic parameters estimated from plasma and lung tissue have also been reported for
other macrolides in infected animals (56). The AUC of spiramycin, roxithromycin, and
azithromycin in lung tissue increased; clarithromycin decreased, and erythromycin did not
change when the drugs were administered 48 h post infection. Because the plasma AUC0-144 of
tulathromycin in T-7 was 41 and 64% lower than in T-7-LPS and T-7-LPS-CP, respectively, the
decrease of AUC0-144 in lung tissue accumulation (AUC0-144) may not be attributable to changes
in plasma concentration (Table 2.3 and Figure 2.3). Even though the plasma AUC was
numerically higher in LPS treated animals, this was not reflected in the lung figures. The
lung:plasma ratios of AUC0-144 were 3.79 and 2.26 for dose groups T-7-LPS and T-7-LPS-CP,
respectively, and 7.95 for dose group T-7. Tulathromycin was slowly eliminated from lung tissue
of both T-7-LPS and T-7-LPS-CP dose groups and resided somewhat longer in LPS-treated
than non LPS-animals (Table 2.3).
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Tissue-directed pharmacokinetics has been proposed as one of the mechanisms of local
drug accumulation (3, 4, 8, 14, 15, 18, 19, 30, 40, 53). When azithromycin was administered to
infected mice, the AUC in lung tissue was much lower in leucopenic animals (3). Based on
these results the authors suggested that leucocytes may help to transport macrolides to the site
of infection. However, results might be confounded by a lower plasma concentration in
leucopenic animals. The results obtained in the present study do not allow delineating a
relationship between neutrophils and lung tissue drug accumulation. Several scenarios may
explain this lack of relationship. First, neutrophils may be truly irrelevant in the pulmonary
accumulation of tulathromycin in mice. Second, tulathromycin may not concentrate in
neutrophils from mice or it may concentrate at low level at the given dose. Third, the
accumulation of cells in lung tissue may not have been enough to generate an evident change
in the lung tissue pharmacokinetics of the drug. Lastly, the relationship between time of drug
administration after the challenge (and concentration time profile) and kinetics (movement of cell
from blood to lung) of neutrophils did not match.
In this study, we administered the drug after the challenge based on the initial
manifestation of abnormal clinical signs observed in preliminary studies simulating a field
scenario. Azoulay-Dupuis et al. (1991) determined that the accumulation of azithromycin at the
site of infection was influenced by the time of administration and progression of the disease (3).
In the present study we evaluated drug pharmacokinetics after administration at a fixed time
with regard to the challenge administration. The evaluation of multiple scenarios would provide
valuable information about the potential relevance of inflammation and drug tissue accumulation
or drug kinetics. It is important to highlight that the rate and extent of intracellular accumulation
and release depend on multiple factors including the chemical structure of the drug (9), cell type
(6, 18, 30) cell status (38), extracellular conditions (pH) (21) and type of stimulus (18). Those
factors should be taken into account when designing future studies.
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Neutrophilia also did not affect drug accumulation in the lung in this study. From a
therapeutic standpoint, this may represent an advantage since the dose regimen may not need
to be adjusted based on the cell count in order to reach target therapeutic concentrations. The
prospective evaluation of the mentioned statement using multiple scenarios would certainly
provide valuable information.
In conclusion, we evaluated the pharmacokinetics of tulathromycin in mouse lung tissue
homogenates and plasma in three different dose groups: healthy mice and LPS-challenged
neutropenic and neutrophilic animals. In all dose groups, the distribution of the drug into the
lungs was rapid and persisted at relatively high levels during 6 days post-administration. The
concentration vs. time profile of tulathromycin in lung tissue was not influenced by the intranasal administration of LPS-Ec. Results suggest that neutrophils may not have a positive
influence on tulathromycin accumulation in lung tissue when the drug is administered during
either a neutrophilic or neutropenic state. The microbiological and clinical impacts of these
scenarios need to be evaluated.
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Appendix
Table 2.1. Summary of the LS mean concentration (ng/mL) of tulathromycin in plasma from mice treated with a single s.c. injection of
tulathromycin at 7 and 28 mg/kg body weight
Time point
30 min

1h

24 h

48 h

Group
T-28
T-7-LPS
T-7-LPS-CP
T-7
T-28
T-7-LPS
T-7-LPS-CP
T-7
T-28
T-7-LPS
T-7-LPS-CP
T-7
T-28
T-7-LPS
T-7-LPS-CP
T-7

LS Mean†
11700
6790
6700
3280
792
3870
6920
2060
145
50.8
59.1
103
100
51.1
57.0
60.0

95% CIs†
490-18500
184-11700
1230-12200
1500-5070
214-1370
713-7030
1870-12000
378-3700
26.7-260
13.7-87.9
11.0-107
28.1-180
27.2-174
13.8-88.4
15.4-98.6
16.2-103

Time point
72 h

96 h

120 h

144 h

Group
T-28
T-7-LPS
T-7-LPS-CP
T-7
T-28
T-7-LPS
T-7-LPS-CP
T-7
T-28
T-7-LPS
T-7-LPS-CP
T-7
T-28
T-7-LPS
T-7-LPS-CP
T-7

LS Mean†
109
19.2
5.32
24.4
26.2
16.9
15.9
9.28
19.2
10.9
6.89
10.8
13.6
7.82
6.48
15.4

95% CIs†
20.2-199
5.20-33.2
0.31-10.3
4.50-44.2
7.10-45.4
4.60-29.3
2.93-28.9
2.50-16.0
3.50-34.9
2.00-19.9
1.27-12.5
2.90-18.7
3.70-23.5
0.50-15.2
1.75-11.2
4.20-26.7

† Back-transformed
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Table 2.2. Summary of the LS mean concentration (ng/mL) of tulathromycin in lung tissue homogenate from mice treated with a
single s.c. injection of tulathromycin at 7 and 28 mg/kg body weight
Group
LS Mean†
T-28
15700
T-7-LPS
3940
30 min
T-7-LPS-CP
5240
T-7
4410
T-28
27900
T-7-LPS
3250
1h
T-7-LPS-CP
5500
T-7
3150
T-28
1760
T-7-LPS
1170
24 h
T-7-LPS-CP
1680
T-7
1170
T-28
4770
T-7-LPS
1050
48 h
T-7-LPS-CP
1000
T-7
2070
† Back-transformed for reporting
Time point

95% CIs†
4550-2600
1440-6430
1910-8560
2198-6621
5050-50500
1192-5320
2010-8980
1150-5140
643-2870
213-2140
614-2740
426-1910
1740-7790
305-1800
292-1720
603-3540

Time point
72h

96 h

120 h

144 h

Group
T-28
T-7-LPS
T-7-LPS-CP
T-7
T-28
T-7-LPS
T-7-LPS-CP
T-7
T-28
T-7-LPS
T-7-LPS-CP
T-7
T-28
T-7-LPS
T-7-LPS-CP
T-7

LS Mean†
4800
889
680
1950
4760
824
879
1690
4240
516
926
1230
3860
1060
750
1020

95% CIs†
1400-8210
325-1450
123-1240
715-3196
1380-8130
301-1350
159-1600
619-2770
1550–6940
189-844
338-1510
359-2110
1120-6590
308-1810
218-1280
375-1670
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Table 2.3. Summary of the pharmacokinetic parameters of tulathromycin in lung tissue homogenate and plasma in mice treated with
a single s.c. injection of tulathromycin at 7 and 28 mg/kg body weight
Group
Pharmacokinetic
T-28

T-7

T-7-LPS

T-7-LPS-CP

Parameter*
Plasma

LH

Plasma

LH

Plasma

LH

Plasma

LH

HL_Lambda_z (h)

18.1

112

13.5

82.0

16.5

213

17.6

144

Tmax (h)

0.50

1.00

0.50

0.50

0.50

0.50

1.00

1.00

Cmax (ng/mL)

11700

27900

3300

4410

6790

3940

6920

5500

Clast (ng/mL)

13.6

3860

15.4

1020

7.82

1060

6.48

750

AUClast (hr*ng/mL)

152000

869000

31000

246000

52600

199000

88100

199000

AUCinf_obs (hr*ng/mL)

152000

1500000

31200

378000

52800

487000

88300

356000

AUMClast
(hr*hr*ng/mL)

599000

45000000

274000

15700000

252000

8670000

259000

9330000

MRTINF_pred (h)

4.16

148

8.91

138

4.99

287

3.03

177

AUC(0-144)LH:Plasma
ratio

5.77

7.95

3.79

2.26

*Dispersion data of the PK parameters are not presented because PK parameters were estimated based on least square means
derived from the naïve pooling from each sample point.
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Table 2.4. Wet-to-dry weight ratios of lung tissue from BALB/c mice
Time
point
30 min

1h

24 h

48 h

Dose group

Mean

SD

%CV

T-7
T-7-LPS
T-7-LPS-CP
T-7
T-7-LPS
T-7-LPS-CP
T-7
T-7-LPS
T-7-LPS-CP
T-7
T-7-LPS
T-7-LPS-CP

3.18
4.22
4.69
4.37
4.26
4.75
4.18
4.47
5.05
4.78
4.64
4.81

0.65
0.38
0.14
0.11
0.15
0.17
0.21
0.12
0.10
1.30
0.15
0.46

20.3
9.07
3.16
2.53
3.53
3.65
5.08
2.85
2.02
27.2
3.24
9.60

Time point
72 h

96 h

120 h

144 h

Dose group

Mean

SD

%CV

T-7
T-7-LP
T-7-LPS-CP
T-7
T-7-LPS
T-7-LPS-CP
T-7
T-7-LPS
T-7-LPS-CP
T-7
T-7-LPS
T-7-LPS-CP

3.95
4.87
5.18
4.32
4.96
4.95
4.59
4.71
5.09
4.28
4.97
5.03

0.28
0.22
0.23
0.25
0.62
0.28
0.20
0.32
0.19
0.26
0.77
0.20

7.05
4.70
4.49
5.73
12.6
5.67
4.28
6.81
3.90
6.12
6.45
3.99
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Table 2.5. Summary of white blood cell count in BALB/c-c mice

Dose Group

WBC
(x103/uL)

N
%

L
%

M
%

E
%

B
%

R
%

N
(103cells/uL)

L
(103cells/uL)

M
(103cells/uL)

CT-LPS-CP (n=7)
Mean
0.93
5.93 89.1 0.37 2.79 0.26 0.08
0.04
0.84
0.00
SD
0.27
4.79 6.88 0.44 1.77 0.34 0.02
0.01
0.26
0.00
CV
0.29
0.81 0.08 1.18 0.64 1.33 0.32
0.29
0.32
2.65
CT-LPS (n=7)
Mean
7.24
43.2 52.9 0.97 1.75 0.15 4.03
3.17
3.81
0.07
SD
1.64
7.00 6.92 0.32 0.98 0.05 0.64
1.02
0.83
0.03
CV
0.23
0.16 0.13 0.34 0.56 0.33 0.16
0.32
0.22
0.38
CT-NT (n=10)
Mean
6.19
10.6 83.5 1.15 1.95 0.25 3.24
0.69
5.18
0.07
SD
2.94
2.05 1.33 0.28 0.51 0.11 0.48
0.37
2.45
0.04
CV
0.47
0.19 0.02 0.24 0.26 0.44 0.15
0.54
0.47
0.54
WBC white blood cell count; N:Neutrophils; L: Lymphocytes; M: Macrophages; E: Eosinophils; B: Basophils; R: Reticulocytes
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Figure 2.1. Intra-peritoneal administration of cyclophosphamide.
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Figure 2.2. Intra-nasal administration of LPS Ec to anesthetized mice.
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Figure 2.3. Intra-nasal administrations of LPS-Ec to anesthetized mice.
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Figure 2.4. LS means concentration (±SE) (ng/mL) of tulathromycin in plasma from mice
treated s.c. with tulathromycin at 7 mg/kg. (For T-7-LPS at 30 min and 96 h n=4. For T7LPS-CP at 30 min, 24 and 48 h, n=4 and at 72 h n=3. For T-7 30 min and 96 h n=4)
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Figure 2.5. LS means concentration (±SE) of tulathromycin in lung tissue homogenate
(ng/g) and plasma (n/mL) from mice treated s.c. with tulathromycin at 7 and 28 mg/kg
(For T7 at 48 h, n=4)
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Figure 2.6. LS means concentration (±SE) (ng/mL) of tulathromycin in lung tissue
homogenate from mice treated s.c. with tulathromycin at 7 mg/kg. (For T7- LPS-CP at 48
h and 72 h, n=4, For T7 at 48 h, n=4)
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Figure 2.7. Linear regression concentration of tulathromycin in lung tissue vs. wet to dry
ratio (from 72 to 144h) for T-7 LPS (R2= 0.01).
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Figure 2.8. Linear regression concentration of tulathromycin in lung tissue vs. wet to dry
ratio (from 72 to 144h) for T7-LPS-CP (R2= 0.03).
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Figure 2.9. Number of neutrophils (mean ± SD) in blood from BALB/c mice.
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Chapter 3:

AN ACUTE REVERSIBLE EXPERIMENTAL MODEL OF
PNEUMONIA IN PIGS: TIME RELATED HISTOLOGICAL
AND CLINICAL SIGNS CHANGES
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Abstract
The objective of this study was to evaluate the long-term survival rates, clinical
response, and lung gross and microscopic changes in pigs treated intra-tracheally with
lipopolysaccharide of Escherichia coli 0111:B4 (LPS-Ec).Healthy pigs were randomly
allocated to 3 groups; (i) no-LPS-Ec (n=1), (ii) LPS-Ec-T1 (1 mg/mL, 10 mL/pig) (n=7)
and (iii) LPS-Ec-T2 (0.5 mg/mL, 10 mL/pig) (n=6). Two pigs from each dose group were
euthanized at 24 (n=3 for T1), 48 and 144 h post-LPS-Ec challenge. LPS-Ec-treated
animals showed macroscopic lesions in middle lobes of the lung. A reversible
recruitment of macrophages and neutrophils was observed at 24, 48, and 144 h postLPS-Ec challenge. The highest cellular infiltration level was observed at 24 h after
challenge. The highest clinical scores were evident in both experimental dose levels
within 3 and 5 h after LPS-Ec administration. The administration of LPS-Ec, under the
conditions evaluated, can be used to induce a reproducible model of acute pulmonary
inflammation in pigs.

Keywords: Lung, inflammatory model, pigs, lipopolysaccharide
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Introduction
Pneumonia represents one of the most important pathological conditions both in
veterinary and human medicine. Information about pathogenesis and treatment of this
disease is generated from clinical cases. However, a considerable amount of the
available data is based on the use of experimental animal models. Animal models of
pneumonia have been used to (i) unravel the pathogenesis of pneumonia (17, 18), (ii)
describe details about inflammatory response (11), and (iii) evaluate disposition and
efficacy of drugs (7).
Pneumonia models have been induced using different types of challenges
including; physical factors (7), microorganisms (Actinobacillus pleuropnemoniae,
Pseudomonas, etc.) (2, 11, 15) and toxins (lipopolysaccharide of Escherichia coli, etc)
(1, 8, 20). Lipopolysaccharide (LPS) is an extremely active immune stimulant substance
from microbiological origin (4). Once recognized by cell membrane receptors (Toll like
receptor type 4), LPS triggers a dose-dependent acute inflammatory response that can
be used to study acute pneumonia (9, 10, 12).
Appropriate experimental models allow for controlled reproducible and
predictable responses and for the design of experiments for particular objectives.
However, a clear understanding of the model is necessary if it is to be used
appropriately. Characteristics of the model will be dictated by factors involving the
challenge (type, dose, route of administration, etc) and host (species, breed, age,
immune status, etc.).
Even though LPS-induced pig pneumonia models have been reported (1, 8, 20),
they have not been described in a manner that can be applied to a wide range of
circumstances. Limited information is available regarding long-term survival rates (>3
days), dose dependent clinical and histological response, variability in the pulmonary
response, and long term course of lesions. In addition, authors have used guinea pigs
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(1) and piglets (8, 21) instead of growing pigs from commercial units, which would in fact
represent the target population. All these elements need to be considered when
designing acute pneumonia studies using the LPS model in pigs.
The objective of the present study was to evaluate the parameters of the intratracheal, two-dose LPS-Ec model of acute pneumonia in growing pigs, including the
long-term survival rates, clinical response, and both macroscopic and microscopic
changes in the middle lobe and caudal lobe of the lung.

Materials and methods
Animals and housing
Fourteen clinically healthy Duroc x Landrace pigs (mean bodyweight ± SD 25.6 ±
1.47 kg) (female n=7 and male n=7) were purchased from Bailey Terra Nova Farms (a
local commercial source). The animals were housed together in a common pen adhering
to standard procedures established at Pfizer Animal Health. Pigs had ad-libitum access
to a standard swine grower ration and drinking water and were acclimatized to the
building/pen for 7 days prior to dosing. Treatment of the pigs was in accordance with
regulations (9 CFR Parts 1, 2 and 3) promulgated from the USDA Animal Welfare Act
and the conditions specified in the Guide for the Care and Use of Agricultural Animals in
Agricultural Research and Teaching (Federation of Animal Science Societies,
Champaign, IL, USA., First Revised Edition, 1999). Before initiation of the study,
procedures involving the care or use of the pigs were reviewed and approved by the
Pfizer Animal Health Institutional Animal Care and Use Committee (IACUC).

Inclusion criteria
Animals with no signs of illness or infection as determined by a pre-dose physical
inspection conducted by personnel trained in swine management were included in the
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study. None of the animals had received antimicrobial therapy within 7 days of the start
of the study. Likewise, none of the animals had been treated with glucocorticoids,
immunotherapeutic, or other anti-inflammatory agents within 30 days prior to the
scheduled start of the study.
Study design
In this parallel-designed study, pigs were randomly allocated to one of three
groups: no treatment (NTX) (n=1), treatment 1 (T1), (n=7) and treatment 2 (T2), (n=6).
The pig in NTX group was the non-treated control. Animals in T1 and T2 received a
single intra-tracheal dose of LPS-Ec at 1 mg/mL (10 mL/pig) and 0.5 mg/mL (10 mL/pig),
respectively.
Preparation of inoculums
Lipopolysaccharide from Escherichia coli 0111:B4 purified by phenol extraction
was purchased from Sigma Aldrich, USA (Lot Number 129K4025). The LPS-Ec powder
was re-suspended in saline solution (NaCl 0.9%) to obtain final concentrations; 0.5 mg
of LPS-Ec/mL and 1 mg of LPS-Ec/mL. The same inoculum volume (10 mL) was used
for all the LPS-Ec treated animals.
Administration of inoculum
Animals were physically restrained on standing position and a red rubber latex
catheter (12 French) was placed intra-tracheally using a mouth opener device. The
catheter placement was confirmed by air movement through the catheter. Afterwards,
the inoculum was instilled into the mid-section of the trachea using a syringe. The
syringe was flushed with air twice to ensure a complete administration of the inoculum.
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Sampling design
Clinical signs were recorded by the blinded attending veterinarian and gross
pathologic changes in the lungs were recorded by a blinded board certified veterinary
pathologist. Clinical signs and gross pathologic changes were evaluated during a period
of 0-144h post-LPS-Ec administration according to the schedule presented in Table 3.1.
Clinical signs were assessed using a scoring system as presented in Table 3.2. After the
last sample was collected, animals were anesthetized by an intramuscular injection of
Telazol® injectable solution (tiletamine / zolazepam Fort Dodge Animal Health, Fort
Dodge, IA, USA) with xylazine and then exanguinated.
Post-mortem gross pathologic and histopathologic observations
After euthanasia, lungs were removed from the animal and gross pathologic
observations made by a pathologist. Briefly, lungs were inflated using approximately 600
mL of 10% buffered formalin instilled intra-tracheally allowing the lung to fix for at least 5
minutes. Then, the lungs were positioned with dorsal surface up on a cutting board.
Lung tissue samples (approximately 2×1×0.5 cm) were obtained from the right (n=4) and
left lobe (n=4). Samples captured portions of the cranial and middle lobe, primary
bronchus and caudal lobe. Samples were placed individually into 10% buffered formalin
for at least 24 h.
Samples for histopathology analysis from the right lung of the control animal
(Animal number 5686), from both lungs of one animal in T1 (animal number 5684) at 24h
post-LPS challenge and left lung of one animal of T1 (animal 5688) and T2 (animal
5681) at 48h post-LPS-Ec challenge were not taken since lung tissue was used for other
proposes not directly related with the objective of this study. Sampled tissues from all
animals were examined by the same pathologist using light microscopy. Morphological
changes included but were not limited to: hemorrhage, interstitial edema, necrosis,
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neutrophil and/or macrophage infiltration, and atelectasis. Morphologies (histopathology
findings) were more fully described with topographical “locators” and “modifiers.” All
prepared sections were scored by a blinded board certified pathologist (DGT) in terms of
severity as follows: GRADE 1 = minimal / very few / very small, GRADE 2 = mild / few /
small, GRADE 3 = moderate / moderate number / moderate size, GRADE 4 = marked /
many / large, GRADE 5 = massive / extensive number / extensive size.
Results
The LPS-Ec inoculum was successfully instilled intra-tracheally in all the
experimental animals. None of the animals coughed nor adversely reacted to the
endotoxin challenge procedure, which ensured a consistent and complete inoculum
administration. None of the animals died during the study. All the experimental animals
were euthanized at the pre-assigned terminal sampling time meeting all the criteria
established by the IACUC for maintaining the experimental animals alive during the
study.

Clinical signs
All the experimental animals were considered clinically healthy at the pre- LPSEc administration. Following LPS-Ec administration, all of the animals experienced
changes at their first clinical score observation (3 h post-LPS-Ec administration). Clinical
observations scores are presented in Table 3.3. None of the clinical scores were higher
than 2 (scale of 0-3) for any of the dose levels and minimal changes were observed in
the general health score. Changes in respiratory score were evident at both dose levels
at 3 h post-challenge. The highest scores were recorded in all the animals at 3 and 5 h
post-LPS-Ec administration for the lower and higher dose levels, respectively.
Afterwards, the score decreased towards pre-LPS-Ec administration (Score=0). All the

89

animals returned to score of 0 after 56 h post-LPS-Ec administration. Attitude change
scores were comparable to respiratory scores. Maximum score changes were observed
at 3 and 5 h post-LPS-Ec administration (Table 3.3).
The visual inspection of the clinical assessment scores indicated a tendency to
revert to normal (score=0) after reaching maximal values.

Gross pathology changes
No macroscopic lesions were observed in the lungs from the non-LPS-Ec-treated
animal. Gross abnormalities in the lung were observed in all the treated animals at 24 h
post-challenge (Figure 3.1). Gross changes were mainly observed bilaterally at the
cranial and middle lobes. The abnormalities were characterized by extensive areas of
red to dark red discoloration and firm consistency. No evidence of differences was
noticed between either of the LPS-Ec doses levels in terms of qualitative characteristics
and magnitude of the lesions. Gross pulmonary changes were also found at 48 and 144
h post-treatment but gross pathology changes tended to be less severe with time.
Microscopic changes
Lungs from all the LPS-Ec-treated animals exhibited histopathological changes.
The primary microscopic findings included alveolar and interstitial inflammation with
neutrophils and macrophages. Also, there was an increased number of leukocytes
(mainly macrophages and/or neutrophils) in the lumen of blood vessels (leukocytosis)
(Figure 3.2, 3.3, 3.4, and 3.5). According with the histopathology findings, animals
treated with 1.0 mg/mL of LPS-Ec (T1) exhibited higher severity scores than those
treated with 0.5 mg/mL (T2) (Figure 3.3, 3.4, and 3.5). The greatest magnitude of
changes was observed at 24 h post-treatment. Severity decreased at 48 and 144 h posttreatment observations in all the experimental animals at both dose levels. In all the
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affected animals, the middle lobes presented more severe histological changes than the
other lobes that were examined. No microscopic changes were seen in the caudal lobes
at the last sample time. Most of these lesions correlated with the gross pathology
findings at necropsy. Table 3.4 summarizes the scores on main microscopic changes in
the pulmonary lobes at 24, 48 and 144 h after LPS-Ec administration.

Discussion and conclusion
Lipopolysaccharide (LPS) is a structural and functional component of the gram negative bacterial outer membrane (5). Scientific evidence indicates that LPS acts as a
potent pro-inflammatory toxin inducing the release and de novo synthesis of mediators
responsible for the pathophysiologic changes associated with gram-negative infectious
pneumonia (13, 16). In the present study, we evaluated the histological and clinical
response of growing pigs from a commercial unit challenged intra-tracheally with LPSEc. The main goal of this study was to identify a LPS-Ec dose that would induce an
acute pulmonary inflammatory response in pigs. For our model, we selected LPS from
Ec due to (i) its high toxicity and consistency in triggering the inflammatory response in
pigs (5, 8, 14, 19), (ii) the ease of handling the inoculum in terms of preparation and
administration, (iii) the ease for dose adjustment/standardization, and (iv) the highly
dose-dependent response (9).
Different studies have reported the use of LPS-Ec to induce an acute
inflammatory response at several dose levels (8, 20). Halloy et al. (2004) used 100 µg/kg
in piglets (8) and Arbibe et al. (1997) used 330 µg /kg in guinea pigs (1). In both studies
experimental animals were euthanized within 24 h. Van Gucht et al. (2003) used a much
lower dose (20 µg/kg in PBS) and kept the animals alive for a longer period of time (14
days) with no abnormal clinical changes (20). We have used the limited data published
from experimental pigs to define a LPS dose and inoculum size for our study. Even
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though LPS-Ec doses used in this study (~200 and 400µg/kg) were higher than those
previously reported for pigs (100 µg/kg, 330 µg/kg and 20 µg/kg), none of the animals in
the present study died during the observation period (0-144 h). This indicates that either
dose could likely be used to induce an aggressive acute inflammatory response while
keeping the pigs alive for at least 144 h.
Abnormal clinical signs, as reflected by health assessment scores, were evident
acutely after the LPS-Ec administration at both dose levels (Table 3.2). Although
doubling the LPS-Ec dose resulted in higher cell accumulation, health assessment
scores only changed slightly.
The most evident gross pathology lesions were observed consistently in the
middle lobe of both lungs (Figure 3.1). Lung areas with gross lesions had higher scores
of microscopic changes. Even though microscopic changes were observed in all the
experimental animals at the three sampling times, gross changes were not observed in
the caudal lobes. By contrast, Halloy et al. (2004) reported macroscopic lesions in the
caudal lobe, indicating a more dispersed distribution of the inoculums (8). It is possible
that the inoculum volume plays a key role. In this study ~0.38mL/Kg of inoculum was
used compared to 1mL/kg used by Halloy et al., (2004) (8). Another difference is that in
the study by Halloy et al., (2004) the inoculum was instilled under general anesthesia
(8). We instilled the inoculum in standing animals. The standing position and movement
of the animals after the inoculation may have resulted in a pulmonary distribution of the
inoculum, into the cranial and middle lower lung compartments. Thus, the relevance of
inoculum volumes and methods of challenge administration may need to be further
evaluated.
The evaluation of gross and microscopic changes as well as the clinical
assessment indicates that LPS-Ec induced reversible pulmonary changes. Even though
there was a clear tendency of inflammatory microscopic changes to move toward
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normality, we have not evaluated the histopathology changes beyond 144 h post-LPSEc administration. Consequently, total reversibility of microscopic changes cannot be
assured. We have not evaluated the effects of multiple LPS administrations but there is
evidence that might indicate that a chronic inflammatory model can be induced by using
multiple LPS administrations (3). On the other hand, some evidence suggests that
induction of LPS-based chronic models may not be appropriate due to the decrease in
the inflammatory response with time due to tolerance (6).
Based on these results we have successfully implemented this model (10mL/Pig
with LPS-Ec at 10mg/mL) in a larger study involving 36 pigs (Chapter 5 and 6) and the
findings have been consistent with those reported here, including normal clinical
condition in pigs at 17 days LPS-Ec post-challenge.
In conclusion, an acute lung inflammatory response was induced by the intratracheal administration of LPS from Ec at two different dose levels. The observed
response included a reversible and marked recruitment of macrophages and neutrophils.
The magnitude of the inflammatory cell infiltration seemed to be dose dependent and
decreased towards baseline levels with time after peak infiltration. Microscopic, gross
pathology and clinical changes were well correlated. Even though an acute inflammatory
response was induced at both dose levels, all the experimental animals survived for the
duration of the study and did not require intervention due to health and welfare concerns.
Therefore, the administration of LPS-Ec, under the conditions described in this study,
can be used to induce a reproducible model of acute lung inflammatory response in
growing pigs.
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Appendix
Table 3.1. Sampling design
Treatment
groups

Hours post-LPS-Ec challenge
3

5

8

12

18

24

28

34

40

48

56

72

80

96

104

120

144

NTX
X-N
X X X
X
X
T124h & T224h
X-N
X X X
X
X
T148h & T248h
X-N
X X X
X
X
X
X
X
X
T1144h & T2144h
X-N
X X X
X
X
X
X
X
X
X
X
X
X
X
X
X
X: Observation taken at this time (clinical evaluation); N: Necropsy performed at this time (Clinical and gross change evaluation of
lung and lung sampling for histopathology); NTX: No LPS inoculation (n=1), T1 treatment group challenged with LPS-Ec at
1mg/mL, total volume of inoculums: 10mL (n=2) (except for T1 at 24h (n=3)), T2: treatment group challenged with LPS-Ec at 0.5
mg/mL, total volume of inoculums: 10mL (n=2).
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Table 3.2. Clinical signs scores
Observation

Attitude
(depression)

Score
0
1

2

3

0
Respiratory
Distress

1
2
3

General
Condition
(includes appetite
evaluation)

0
1
2
3

Clinical Description
Normal – Pig is up and active when entering the room or when approaching.
Mild depression – Pig is slightly inactive, but gets up after being approached; pig moves slowly and
appears lethargic; shows some interest in food and social interaction, but stays active only for a
few minutes; animal may appear gaunt and have a rough coat.
Moderate depression – Pig shows pronounced inactivity and gets up only after light back pressure;
displays little or no interest in food and/or social interaction; tends to lie down almost immediately
and/or stands with head down; noticeably gaunt and coat is rough; staggers and appears slightly
uncoordinated at the walk.
Severe depression/moribund – Pig is moribund, unresponsive to stimuli, unable to get up or does
so with difficulty; shows no interest in surroundings, food, or social interaction; appears anxious;
should be euthanized for humane reasons.
None – Respiratory movements are subtle, superficial, and can be observed only when animal is
quietly lying down.
Mild – Respiratory movements are obvious and predominantly abdominal.
Moderate – Respiratory movements are exaggerated, entirely abdominal, and labored.
Severe – Respiration is very labored and entirely abdominal; pig breaths through mouth
(continuously or intermittently); nose and/or ears are cyanotic; should be euthanized for humane
reasons.
Clinically normal appearing animal
Slightly abnormal condition
Moderately abnormal condition
Severely abnormal condition
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Table 3.3. Clinical score changes in pigs treated intra-tracheally with LPS of Ec at two dose levels (n=14)
Treatment Group 5 mg/pig
ID

CS

5683

A
RD
GH
A
RD
GH
A
RD
GH
A
RD
GH
A
RD
GH
A
RD
GH
A
RD
GH

2
2
0
2
2
0
1
2
1
2
1
0
1
1
0
2
2
0
1
0
0

2
1
0
2
2
0
2
2
0
1
2
0
1
2
0
2
2
0
1
0
0

0
0
0
0
0
0
0
0
0
2
2
0
0
2
0
2
2
0
0
0
0

0
2
0
0
0
0
0
0
0
1
2
0
1
1
0
2
2
0
0
0
0

0
0
0
0
0
0
1
1
0
0
0
0
2
1
0
2
0
0
0
0
0

0
0
0
0
0
0
2
1
0
0
0
0
1
0
0
2
0
0
0
0
0

Time post LPS
Administration
(h)

3

5

8

12

17

24

5685

5679

5688

5680

5676

NTX

Treatment Group 10 mg/pig

Score

ID

CS

5684

A
RD
GH
A
RD
GH
A
RD
GH
A
RD
GH
A
RD
GH
A
RD
GH
A
RD
GH

2
2
0
2
2
0
2
2
0
2
2
0
2
2
0
2
2
0
2
2
0

1
2
1
1
2
0
2
2
0
2
2
0
2
2
0
2
2
0
2
2
0

2
2
0
0
0
0
2
2
0
2
2
0
1
2
0
2
2
0
2
2
0

0
2
0
0
0
0
2
2
0
1
2
1
2
2
0
1
2
0
2
2
0

0
2
0
0
0
0
0
2
0
2
1
0
0
1
0
2
0
0
1
0
0

0
0
0
0
0
0
0
0
0
1
1
0
0
0
0
0
0
0
1
0
0

1
1
0
1
0
0
0
0
0
0
0
0

1
1
0
1
1
0
0
0
0
0
0
0

1
1
0
1
1
0
0
0
0
0
0
0

1
1
0
0
1
0
0
0
0
0
0
0

0
0
0
1
0
1

0
0
0
0
0
0

0
0
0
0
0
0

Time post LPS
Administration
(h)

3

5

8

12

17

24

28

34

40

48

56

72

80

5687

1
1
0
0
0
0
0
0
0
1
1
0

0
0
0
0
0
0
0
0
0
1
1
0

0
1
0
0
0
0
0
0
0
0
0
0

1
0
0
0
0
0
0
0
0
0
0
0

5689

5681

0
0
0
0
0
0

0
0
0
1
0
0

0
0
0
1
0
0

5678

5682

5677

28

34

40

48

56

72

80

Score

ID: identification; NTX; control animal; A: attitude; RD: respiratory distress; GH: general health. Results beyond 80h are not included. All
the experimental animals had a clinical score of 0 between 96 and 144 h post-LPS-Ec administration for the three scores evaluated.
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Table 3.4. Severity of Main Histological Findings in Pulmonary Samples from Pigs Treated Intratracheally with LPS of Ec at two dose levels (n=13)

Treatment
Animal ID (56-)
Left Cranial
Acute alveolar
Inflammation
Acute Interstitial
Inflammation
Leukocytosis
Left Middle
Acute alveolar
Inflammation
Acute Interstitial
Inflammation
Leukocytosis
Left Caudal
Acute alveolar
Inflammation
Acute Interstitial
Inflammation
Leukocytosis
Left Primary Bronchi
Acute alveolar
Inflammation
Acute Interstitial
Inflammation
Leukocytosis
Right Cranial
Acute alveolar
Inflammation
Acute Interstitial
Inflammation
Leukocytosis
Right Middle
Acute alveolar
Inflammation
Acute Interstitial
Inflammation
Leukocytosis
Right Caudal
Acute alveolar
Inflammation
Acute Interstitial
Inflammation

Time Post-dosing/ Group/ Animal ID
24 hr
48 hr
144 hr
LPS
LPS
LPS
LPS
LPS
LPS
NTX
5
10
5
10
5
10
mg/pig mg/pig mg/pig mg/pig mg/pig mg/pig
86

83

85

87

89

88

79

78

81

80

76

77

82

0

1

1

1

4

-

2

2

-

2

2

1

1

0

0

1

0

1

-

1

1

-

1

2

0

0

0

1

1

0

2

-

0

1

-

0

1

1

1

1

3

4

5

5

-

1

2

-

2

2

1

1

1

1

1

1

3

-

0

2

-

2

2

0

0

1

2

1

1

3

-

0

1

-

1

1

1

1

1

1

2

0

3

-

2

3

-

2

0

1

1

0

1

1

0

1

-

1

2

-

1

1

1

0

0

2

2

1

1

-

0

1

-

1

1

1

1

0

2

2

2

3

-

2

2

-

1

0

1

0

0

1

1

1

1

-

2

1

-

1

0

0

0

0

2

1

1

2

-

1

1

-

1

1

0

1

-

2

4

1

1

2

2

2

2

0

0

1

0

-

1

1

0

0

1

1

2

1

0

1

0

0

-

1

1

1

1

1

0

1

2

1

1

1

1

-

4

4

5

5

2

2

3

2

4

1

2

1

-

1

1

2

2

0

0

2

1

2

2

2

0

-

2

1

3

1

2

0

2

1

1

1

1

1

-

2

3

1

4

2

2

2

1

4

1

1

1

-

0

1

0

2

1

2

1

1

2

0

2

0
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Table 3.4. Continued

Treatment
Animal ID (56-)
Leukocytosis
Right Primary Bronchi
Acute alveolar
Inflammation
Acute Interstitial
Inflammation
Leukocytosis

Time Post-dosing/ Group/ Animal ID
24 hr
48 hr
144 hr
LPS
LPS
LPS
LPS
LPS
LPS 5
NTX
5
10
10
5
10
mg/pig
mg/pig mg/pig
mg/pig mg/pig mg/pig
86

83

85

87

89

88

79

78

81

80

76

77

82

-

1

1

1

1

1

1

0

1

1

1

1

2

-

1

1

1

4

2

2

2

1

2

1

1

0

-

0

0

0

1

0

1

1

0

1

1

0

0

1
1
1
1
1
1
2
1
1
1
1
1
NTX; no LPS treatment. Samples from the caudal lobes taken at its cranial (A) and caudal
levels (B). Numbers in columns indicate grade of severity: -= No lobe examined; 0= No
lesion; 1=Minimal; 2=Mild; 3= Moderate; 4= Marked; 5= Severe. Acute alveolar
inflammation was characterized by focal to diffuse infiltration of alveolar spaces with low to
abundant numbers of macrophages and/or neutrophils. Acute interstitial inflammation was
characterized by focal to diffuse thickening of the inter-alveolar septa by infiltration with
variable numbers of macrophages and lesser neutrophils. Leukocytosis was characterized
by increased numbers of leukocytes (mainly macrophages or neutrophils) in the lumen of
large, medium, small blood vessels and capillaries. In some of the cases those leukocytes
appear adhered to the endothelia. Congestion and/or hemorrhage were characterized by
increased amount of blood in the lumen of blood vessels and capillaries (congestion) or by
extravasation of red blood cells from blood vessels or capillaries into adjacent pulmonary
tissue or alveolar spaces (hemorrhage). Atelectasis was characterized by focal or
multifocal and coalescing areas where the alveolar spaces were markedly reduced in size
and the tissue was collapsed. Commonly the alveoli in those areas were infiltrated with
variable numbers of foamy macrophages and multifocal minimal to mild fibrin deposition.
Peribronchial/peribronchiolar lymphoplasmacytic inflammation was characterized by
nodular accumulation of variable numbers of lymphocytes and plasma cells in the
periphery of the bronchi and/or bronchioles. Bronchial/bronchiolar inflammation was
characterized by infiltration of bronchial or bronchiolar lumen with variable numbers of
neutrophils. Chronic pleural inflammation (Pleuritis) was characterized by hypertrophy of
the mesothelial cells, fibrosis, and inflammatory infiltration composed mainly of
neutrophils, macrophages mixed with lesser lymphocytes, plasma cells, and eosinophils.
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Figure 3.1. Lung gross changes induced by intra-tracheal administration of LPS-Ec.at 24 h postchallenge.
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Figure 3.2. Lung histologic changes induced by intra-tracheal administration of Ec. Lung
sections from saline (X 40). The pictures are representative of samples taken from areas with
evident gross changes (LPS treated pigs). No gross changes were observed in the control
animal; therefore picture is representative of samples taken from middle lobe.
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Figure 3.3. Lung histologic changes induced by intra-tracheal administration of Ec. Lung
sections from LPS-Ec-treated pigs at 0.5 mg/mL (X40) at 24 h post-LPS Ec administration.
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Figure 3.4. Lung histologic changes induced by intra-tracheal administration of Ec. Lung
sections from LPS-Ec-treated pigs at 1 mg/mL (X 40) at 24 h post-LPS Ec administration. The
pictures are representative of samples taken from areas with evident gross changes (LPStreated pigs).
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Figure 3.5. Lung histologic changes induced by intra-tracheal administration of Ec. Lung
sections LPS-Ec-treated pigs at and 1 mg/mL at 24 h post-LPS Ec administration. The pictures
are representative of samples taken from areas with evident gross changes (LPS treated pigs).
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Chapter 4:

A PILOT ASSESSMENT OF TRACHEO-BRONCHIAL
FIBERSCOPY AND BRONCHIAL MICRO-SAMPLING PROBES
TO EVALUATE ANTIMICROBIAL CONCENTRATIONS IN
LOWER RESPIRATORY AIRWAYS IN PIGS
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Introduction
Infection site concentrations are linked to the efficacy of any antimicrobial treatment.
Free drug plasma concentrations are considered surrogate for the concentrations at the site of
infection (4, 10). However, the actual concentration-time profile at the site of infection can differ
from that in plasma, questioning in some circumstances, its value as a surrogate of peripheral
drug concentrations (4, 10). In the lung, determination of drug concentration is often
accomplished by homogenizing lung tissue and broncheoalveveolar lavage (BAL). However,
these techniques often provide conflicting information and/or have many shortcomings from the
experimental design standpoint (7). More sophisticated techniques have also been applied to
study pulmonary drug distribution including positron emission tomography and microdialysis, but
their applicability in veterinary medicine is limited to a small number of experimental
circumstances and logistical concerns (2, 6, 13-15).
This study seeks to find an alternative method to sampling drug concentrations in lung
tissue that is faster, minimizes labor, is appropriate in multiple sampling designs, and provides
meaningful information. There are few convenient sampling procedures available to harvest
bronchial epithelial lining fluid (BELF) in pigs. Bronchial micro-sampling (BMS) probes have
been used experimentally in human setting and are likely to provide a valuable alternative for
pigs, but are yet to be tested in veterinary species (8, 9, 16). The objective of this study was to
evaluate the use of BMS probes (BC-402C; Olympus; Tokyo, Japan) for quantification of
tulathromycin BELF in pigs.
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Materials and methods
Animals and housing
Four healthy female Duroc x Landrace pigs (20-30 kg) were purchased from a local
commercial source. Treatment and housing conditions of the pigs were in accordance with
regulations outlined in the USDA Animal Welfare Act (9 CFR Parts 1, 2 and 3). Procedures
involving the care or use of the pigs were approved by a Pfizer Institutional Animal Care and
Use Committee.

Treatment and sampling design
Animals (n=3) were dosed with tulathromycin at 2.5 mg/kg (Draxxin Injectable Solution,
Pfizer Animal Health, New York, NY) at the supplier location and transferred to Pfizer Animal
Health for procedural work approximately 23 h after dosing. The remaining animal was used as
an untreated control. Blood samples were taken by venipuncture 24 hours after the
administration of tulathromycin. Afterwards, animals were euthanized by captive bolt stunning
followed by exsanguination. BELF was gathered from each animal using bronchial microsampling (BMS) probes (Model BC-402C Olympus; Tokyo, Japan) as described previously in
humans (8, 9, 16) (Figure 4.1). Immediately after euthanasia, the trachea was exposed and a
fiber-optic flexible endoscope (Olympus, model XP-10) and a BMS probe were inserted into the
trachea and directed into the middle lobe following the bronchi until resistance was met. The
sampling portion of the BMS probe was uncovered from the protective sheath and was placed in
contact with the bronchus wall for approximately 20 seconds. This was visually verified in all
animals. The sample portion of the probe was drawn back into the sheath to avoid
contamination before removing the device from the respiratory airways. Three independent
samples were taken from a secondary bronchus at the right and left middle lobes of each
experimental animal (6 bronchial samples/animal). The cotton tip (sample portion) was removed
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from the rest of the sampling device, collected into a polypropylene tube, transported on wet ice
(~0°C) and stored refrigerated until analysis. The fluid volume gathered from each probe was
estimated by weight as previously reported (8, 9, 16). After the BMS procedures, lung tissue
was collected from each animal. The tissue was individually homogenized and placed into
plastic containers. Samples were kept at -10 °C until analysis.

Analytical methods
Tulathromycin assays
Probe extracts, lung homogenate and plasma samples were analyzed for tulathromycin
content by high performance liquid chromatography (HPLC) with tandem mass spectrometry
detection (LC-MS/MS) following procedures described by Galer et al. (2004) (5) and Cox et al.
(2010) (3). Roxithromycin was used as internal standard (12).

Bronchial epithelial lining fluid assay
Drug extraction procedures from probes have been described previously for multiple
compounds (8, 9, 16). Briefly, the method for extraction of tulathromycin from the probe starts
with the introduction of 2 mL of 20 mM pH 4 ammonium acetate:acetonitrile (50:50 v:v) into the
tube containing the sampling probe. The sample was vortexed for approximately 1 min and then
sonicated for 2 min. A 50 µL sub-sample aliquot was spiked with 200 µL of roxithromycin (25
ng/mL) into a glass tube, vortexed for 1 min and centrifuged at ~1500 RCF (~3000 RPMs) for 10
min. the supernatant (~200 µL) was transferred into a glass vial and 5 µL were injected into the
system for analysis. The calibration range was 1.0 to 500 ng/mL (R2 >0.99) using 7 calibration
standards. The bias for the calibration standards ranged from -10.2 to 10.0%. Study samples
were analyzed in one run. Three quality control samples (2.5, 25 and 100 ng/mL) were included
in the analysis. The bias in the assays of the quality control samples ranged from -2.0 to 10.8%.
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Recovery of tulathromycin from probes was assessed by spiking BMS probes in triplicate with
tulathromycin at 100 ng/mL. Probes were processed as described above for the study samples.
Recovery of tulathromycin from probes was determined to be >94%.
Results
Tulathromycin was detected in all the matrices studied from treated animals but not in
matrixes from the control animal. The concentrations (mean ± SD) of tulathromycin in plasma
and lung homogenate at 24 h after dosing were 41.2 ± 15.4 ng/mL and 3900 ± 431 ng/g,
respectively and were consistent with results published in the literature (1).
Tulathromycin concentrations were notably high in the BELF (Table 4.1). Consistent
drug concentrations were obtained from equivalent anatomical sites from the same animal (4.
2). The concentration of tulathromycin in BELF probes and the intra-site variability are provided
in Table 4.1. Inter-site and inter-animal variability of tulathromycin concentration in BELF are
shown in Table 4.2. This demonstrates that the drug accumulates in the airway compartment of
the lungs from pigs. We did not evaluate whether the harvested BELF sample was a free-cell
sample or whether the drug was unbound. Consequently, we cannot assure that the
concentrations obtained are free extracellular concentrations.
Multiple studies performed in humans using BMS probes recommend the use of three
probes per sample (8, 9, 16). In the present study, we used three probes per sampling site,
however, the drug was quantified from individual probes to provide an objective understanding
from each individual probe sampling performance and provide evidence for the design of future
studies. Results obtained indicate that there is an important inter-probe variability (Table 4.1).
which suggests that the use of multiple probes per sampling site improves the precision of the
data (Table 4.2). Probes with larger contact surfaces might also improve their sampling
performance.
Broncheoalveolar lavage (BAL) is a common technique used to harvest pulmonary
epithelial lining fluid (PELF). Pulmonary epithelial lining fluid represents the cell-free fluid
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obtained from BAL after normalization with urea (11). Thus, the drug concentration in PELF
represents lower intra-airway and alveolar composite concentrations. This indicates that
concentration results in PELF obtained by BAL have poor anatomical resolution. Although we
have identified some limitations in terms of applicability, BMS probes provide many advantages
when compared with traditional procedures to study pulmonary drug pharmacokinetics (Table
4.3). We have successfully conducted a larger study in 36 pigs using BMS probes as BELF
sampling device (Villarino, chapter 5 and 6). Results were consistent with those obtained in the
present study.
In the present study, some probes were contaminated by blood present in the airways.
The presence of blood in the airways was probably consequence of the method of euthanasia
used. In order to reduce the likelihood of extra-pulmonary blood contamination of airways it is
recommended to use anesthesia followed by exsanguination.

Conclusion
The use of BMS probes represents a fast and simple technique for sampling BELF for
quantitation of drugs in pigs, even in large scale studies. In addition, BMS probes allow studying
drug kinetics in the epithelial lining fluid avoiding many of the shortcomings described for
bronchoalveolar lavage (7) and increasing the interpretative value of the data when compared
with lung homogenate and PELF.
In conclusion, in this study we have identified and described many of the advantages
and some of the limitations of BMS probes to harvest BELF. These were not available in the
literature and represent valuable information to be considered when designing future lung
pharmacokinetic studies in veterinary species. Results obtained in the present study provide
evidence to justify the use of BMS probes in a larger scale in order to gain a full understanding
about their applicability of BMS probes on the study of pulmonary drug pharmacokinetics in
animals.
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Appendix
Table 4.1. Concentration (ng/ml) and intra-site probe variability of tulathromycin in BELF in pigs
dosed at 2.5 mg/kg i.m.

Animal
ID

Anatomical Sampling Site
Left Bronchi
Right Bronchi
Probe
Probe
Mean SD %CV
Mean SD %CV
1
2
3
1
2
3

665

2970* 4680 1930 3190 1390

43.5 2920 2710 1400 2340 824

35.1

666

4060* 3640 2060 3250 1050

32.4 3690 3360 3390 3480 182

5.24

667

1280* 2830* 963 1690 999

59.1 1840* 1220* 2180* 1750 487

27.9

* Probe was visibly contaminated with blood
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Table 4.2. Inter-animal variability of tulathromycin concentration (ng/mL) in BELF in pigs dosed
at 2.5 mg/kg i.m..
Anatomical Sampling Site
Animal
Left Bronchus
Right& Bronchus
665
3190
2340
666
3250
3480
667
1690
1750
#
Mean
2710
2520#
SD
885
881
&: Tulathromycin concentration from probes from each site (n=3) per animal were pooled
&

considering three probes a unique sample (8, 9, 16)..
# Drug concentrations from the left and right bronchus were tested statistically using un-paired
student t test (level of significance <0.05). Results indicated no statistical differences (p>0.8)
between both anatomical sites.
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Table 4.3. Advantages and limitations of bronchial microsampling probes to obtain bronchial
epithelial lining fluid (BELF).
Advantages

Limitations
Some species/animals might require

Applicable in multiple species
sedation or anesthesia (e.g. pigs)
Requires the use of a fiberscope and
Quick and minimally invasive procedure
expertise in endoscopy
Since it does not modify the sample site
environment, it can be applied in multiple
sampling protocols.

Animal size

This s decrease variance inflation thus

The use of fiberscope and probes is limited by

increasing power of the design. In addition, the

the larynx/trachea vs. fiberscope diameter.

number of experimental animals can be
considerably reduced.
Analytical technique
Extraction procedures are fairly simple
It would require highly sensitive analytical
Minimize cost and time of the quantification
instruments such as mass spectrometry
It permits sampling pre-defined anatomical

The anatomical site to sample

sites within the organ

The anatomical site to sample is limited by

It allows independent sampling at different

airway/fiberscope diameter and

levels along the airways.

probe/fiberscope length.

117

Figure 4.1. Bronchial micro-sampling probes (BC-402C; Olympus; Tokyo, Japan).
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Chapter 5:

PULMONARY PHARMACOKINETICS OF TULATHROMYCIN IN SWINE:
LUNG HOMOGENATE IN HEALTHY PIGS AND PIGS CHALLENGED
INTRA-TRACHEALLY WITH LIPOPOLYSACCHARIDE OF
ESCHERICHIA COLI
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Abstract
Tulathromycin is a macrolide antimicrobial approved in the US for the treatment and control of
bovine and swine respiratory disease. The objective of the study was to assess the
pharmacokinetics of tulathromycin in lung tissue homogenate (LT) and plasma from healthy and
lipopolysaccharide (LPS)-challenged pigs. Clinically healthy Duroc x Landrace pigs were
allocated to two dosing groups of 36 animals each (group 1 and 2). All animals were treated
with tulathromycin (2.5 mg/Kg). Animals in group 2 were also challenged intra-tracheally with
LPS from Escherichia coli (LPS-Ec) 3 h prior to tulathromycin administration. Blood and LT
samples were obtained from all animals during 17 days post-tulathromycin administration. For
LT, one sample from the middle (ML) and caudal lobes (CL) were taken. Tulathromycin
distributed rapidly and extensively into the lung. The concentration vs. time profile of the drug in
the middle lobe in animals challenged with LPS-Ec (group 2) differs from the concentration vs.
time of tulathromycin from animals from group 1 (p<0.02). These differences are due to a
change in the concentration time vs. of the drug between 0 and 72 h post-tulathromycin
administration. For middle lobe there were statistical differences in drug concentration at 6 h
(p=0.03) and 72 h (p<0.01). For the caudal lobe there were statistical differences at 24 (p<0.02)
and 72 h (P=0.04). The area under the concentration-time curve through 408 h (AUC0-408) for
LTGroup-1-ML, LTGroup-2-ML, LTGroup-1-CL, and LTGroup-2-CL, were 506000, 450000, 504000, and 473000
ng*h/g, respectively. Tulathromycin (AUC0-480) in the lung exceeded the plasma AUC0-408 by
91.3, 78.9, 83.9, and 88.8 fold for LTGroup-1-ML, LTGroup-2-ML, LTGroup-1-CL, and LTGroup-2-CL,
respectively. The drug was slowly eliminated from the lung (terminal half-life >135h for all lobes)
with a LT: plasma ratio > 300 at 17 days post-tulathromycin administration.
In conclusion, the drug distributed extensively and rapidly into the lungs in both groups.
It also persisted in lung tissue at relatively high levels for 17 days post-administration. The
concentration vs. time profile of the drug in the middle and caudal lobe in animals challenged
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with LPS-Ec was influenced by the intra-tracheal administration of LPS-Ec. The clinical
significance of these findings is unknown.
Keywords: tulathromycin, antimicrobial, pig, lung, lipopolysaccharide
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Introduction
Respiratory disease represents one of the most common pathological conditions in
livestock (1). Administration of antimicrobials to treat and control the course of respiratory
disease is part of the health management practices for both pigs and cattle. Tulathromycin
(Draxxin) is a triamilide antimicrobial effective in treating and controlling bovine and swine
respiratory disease (15, 18, 20, 26)
When used as recommended, tulathromycin is a safe drug that requires a withdrawal
time of 5 days. it is rapidly (tmax < 1h) and nearly completely absorbed when administered
following label indications. This drug also has many relevant pharmacokinetic features:
tulathromycin not only distributes extensively into lung tissue but also persists in the lung, at
high concentrations, for a long period of time (apparent elimination half-life ~6 days). The area
under the concentration-time curve (AUC) in lung tissue is more than 60 times higher than the
plasma AUC (5, 19).
Multiple factors affect the distribution and accumulation of a drug in a peripheral
compartment (e.g. blood flow, tissue binding, cellular infiltration) (22). Some of those systemic
and/or local conditions change as a consequence of local inflammation, which may influence the
tissue kinetics of the drug (2). Inflammation is a multifactorial, physiological response to tissue
injury that changes over time. Therefore, it is reasonable to expect that the influence of the
inflammatory response on the tissue kinetics of a drug will also change with time (3, 12).
Tulathromycin has been approved by the FDA to control and treat swine respiratory disease.
Therefore, the drug may be administered to animals at risk of developing respiratory disease
(metaphylactic administration) or sick animals at any of the stages of inflammation (acute, subacute, or chronic stage). In previous pharmacokinetic studies, lung disposition of tulathromycin
was based on LT samples from healthy animals obtained between 12 and 360 h post-
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administration (5, 19). However, no information is available about the pharmacokinetic profile of
the drug in lung tissue or plasma from pigs with a pulmonary inflammatory condition.
The objective of the present study was to assess the pharmacokinetics of tulathromycin
in lungs and plasma from healthy and lipopolysaccharide (LPS)-challenged pigs during a period
between 0 to 408 h post-tulathromycin administration. In this study, we assessed the pulmonary
concentration-time profile of tulathromycin using lung homogenate samples. In a companion
paper, it is reported the concentration-time profile of tulathromycin in bronchial and pulmonary
epithelial lining fluid and bronchoalveolar lavage cells.

Material and methods
Animals and housing
Seventy-eight clinically healthy male and female Duroc x Landrace pigs (20–30 kg) were
purchased from a local commercial source. Drinking water and food was available ad-libitum
throughout the study. Animals were acclimatized for a minimum of 7 days prior to administration
of tulathromycin. Dose calculations were based on bodyweights determined day -1 and 0.
Treatment and housing conditions of the pigs were in accordance with regulations (9 CFR Parts
1, 2 and 3) promulgated from the USDA Animal Welfare Act and the conditions specified in the
Guide for the Care and Use of Agricultural Animals in Agricultural Research and Teaching
(Federation of Animal Science Societies, Champaign, IL, USA., First Revised Edition, 1999).
Before initiation of the study, procedures involving the care or use of the pigs were reviewed
and approved by the Pfizer Animal Health Institutional Animal Care and Use Committee
(IACUC).

Study design
Seventy-two animals were enrolled on the study (36 animals in each dosing group;
group 1: 21 males, 15 females and group 2: 16 males, 20 females). Animals (n=6) were
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allocated randomly to treatments (T01 to T06, representing the sampling time), group (n=2 nonLPS and LPS-treated animals) and pens (n=6) according to a split plot design (1 extra nonenrolled animal). Animals within a group were allocated into 3 pens. Each pen contained 12
animals. Thus, the group represents the whole plot factor, and treatment the split plot factor.
The whole plot was a completely randomized design with a one-way treatment structure.
Treatment administration
Animals in group 1 were administered one intramuscular (i.m.) injection of tulathromycin
(Draxxin Injectable Solution, Pfizer Animal Health, New York, NY) at 2.5 mg/Kg bodyweight in
the neck at time 0. Animals in group 2 were administered 10 mL LPS/animal at -3 h followed by
tulathromycin at time 0.
Administration of LPS-Ec
Preparation of the inoculum
Preparation of the inocula, final volume, and potency was performed as previously
reported (Chapter 3). Briefly, LPS-Ec 0111:B4 purified by phenol extraction was purchased from
Sigma Aldrich, USA (Lot Number 129K4025). The LPS-Ec powder was re-suspended in saline
solution (NaCl 0.9%) to obtain a final concentration of 1 mg/mL. The same inoculum size (10
mL) was used for all LPS-Ec-treated animals.
Administration of the inoculum
Animals were physically restrained in standing position, and a red rubber latex catheter
(12 French) was placed intra-tracheally using a mouth opener device. Catheter placement was
confirmed by air movement through the catheter. Afterwards, the inoculum was instilled in the
middle trachea using a syringe. The syringe was flushed with air twice to ensure complete
administration of the inoculum.
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Health Assessment- Post-Treatment Observations for LPS-treated Animals
As described previously, the intra-tracheal administration of LPS-Ec was expected to
generate a reversible acute inflammatory response. Associated with this, animals were
expected to show signs of respiratory distress and abnormal attitude at three hours after the
LPS challenge. Therefore, we pre-defined the time of tulathromycin administration at three
hours after the administration of the LPS-Ec. For the health assessment, the general condition,
respiratory distress, and attitude scores of the animals were recorded. Table 5.1 presents the
score assessment criteria implemented (Chapter 3). LPS-Ec-treated animals were evaluated at
pre-LPS-Ec and post-LPS-Ec. administration between -3 to 408 h post-tulathromycin
administration, as indicated in Table 5.2.

Blood Collection
Blood (for plasma) was collected during a period of 0–408 h from all animals, following
the scheme presented in Table 5.3.
Euthanasia and Necropsy
After collection of the last blood sample from each treatment group, animals were
anesthetized with Telazol® injectable solution (tiletamine / zolazepam Fort Dodge Animal
Health, Fort Dodge, IA, USA) and xylazine followed by exsanguination. Animals were
euthanized within  5% of the scheduled time. Necropsies of experimental animals from both
groups were performed at 6 different times after the administration of tulathromycin as
presented in 5. 2.
Lung homogenate
For animals enrolled in group 1 (tulathromycin only), 2 lung tissue samples were
collected from the middle and caudal lobe of the lung.
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For animals enrolled in group 2 (tulathromycin and LPS-Ec), lung tissue samples were
collected from areas with macroscopic lesions in the middle lobe. If macroscopic lesions were
not evident samples were taken from tissue that appeared healthy. A second lung sample was
taken from the hemi lateral caudal lobe at a macroscopic normal area. Lung samples were
individually homogenized and then frozen in a plastic container at -80°C until analysis.

Wet-to-dry ratio determination
Two cm x two cm sub-sections of the middle and caudal lobes were taken for wet/dry
ratio determination. Whenever a lesion was present in the middle lobe, a subsample from the
lesion area was collected. Samples were placed in sealed bags for transportation. Samples
were weighed in aluminum container and the wet weight recorded. Then, samples were dried in
an oven at approximately 60°C for 15 days. Samples were then weighed again for wet to dry
ratio determination using the equation;
Wet-to-dry ratio = wet weight (g) / dry weight (g)
Analytical methods
All matrices samples were analyzed for tulathromycin concentration by high performance
liquid chromatography with tandem mass spectrometry detection following procedures
described (8, 11). Roxithromycin was used as an internal standard (23).

Plasma
A 50-µL plasma sample was mixed with 200 µL of acetonitrile containing roxithromycin,
the internal standard, and centrifuged. A 160-µL aliquot of the plasma supernatant was diluted
with 40 µL of 20 mM ammonium acetate, pH 4, and 10 µL was injected into the
chromatographic system. Chromatography was accomplished with a BDS Hypersil C 8 30 x 2.1
mm column (Thermo Fisher Scientific, Waltham, MA, USA), at a flow rate of 0.300 mL/min, and
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with linear gradient chromatography with a mobile phase initially consisting of 80% A (20 mM
pH 4 ammonium acetate) and 20% B (acetonitrile) and was changed to at 0.5 min of 20% A and
80% B. Retention times were approximately 1.0 min for tulathromycin and 1.2 min for
roxithromycin. The mass spectrometer (Sciex API 4000, Foster City, CA, USA) was used in the
positive ion mode using an electrospray ionization source, and positive ions were monitored
with precursor→ product ion pairs of 806 → 577 for tulathromycin and 837 → 679 for
roxithromycin.
The calibration curve (R2>0.99) ranged from 0.5 to 500 (ng/mL), using 11 calibration
standards, and 6 quality control samples (1.95, 3, 18, 30, 195, 300, and 500 ng/mL) were
included. For the quality control samples, the intra-run coefficients of variation ranged from 6.6
to 11.0%, and the intra-run biases ranged from -11.0% to 9.0%. For the calibration curve
samples, the intra-run coefficients of variation ranged from 1.2% to 18.8%, and intra-run biases
for these samples ranged from -11.6% to 6.0%. The inter-run coefficients of variation ranged
from 1.7% to 16.9%, and inter-run biases for these samples ranged from -11.0% to 9.0%.

Lung homogenate samples
Samples were processed as described previously by Galer et al. (2004) (11). Briefly,
0.200 g of the lung tissue sample was homogenized with 0.050 mL of 50 mM phosphate buffer,
pH 6, and 4.95 mL of 0.04 M phosphoric acid. The homogenate was centrifuged, and 0.25 mL
of the supernatant was then mixed with 0.25 mL of 50 mM pH 6 phosphate buffer and 0.25 mL
of internal standard solution, and the entire sample was loaded onto an Oasis MCX 1cc (30 mg)
SPE cartridge. The cartridge was washed with 1 mL of 50 mM pH 6 phosphate buffer, 1 mL of
distilled deionized water, and 1 mL of acetonitrile. Drug was then eluted from the cartridge with
two 0.5 mL volumes of 5% ammonium hydroxide/ 95% acetonitrile. After evaporation under
nitrogen gas, the sample was reconstituted with 0.25 mL of 20 mM pH 4 ammonium acetate and
acetonitrile (80:20 v:v) and then diluted 1:10 with additional ammonium acetate: acetonitrile
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solution. A 10 uL aliquot was injected into the chromatographic system. The calibration curve
(R2>0.99) ranged from 100 to 25000 ng/g lung tissue using 11 calibration standards, and 3
quality control lung tissue samples (200, 2000 and 10000 ng/g) in each analytical run. For the
quality control samples, the intra-run coefficients of variation ranged from 4.7 to 7.6%, and the
intra-run biases ranged from -6.5% to 2.5%. For the calibration curve samples, the intra-run
biases ranged from -6.4% to 9.0%.

Pharmacokinetic and statistical analyses
Plasma concentration data were summarized using descriptive statistics by treatment
and time point. Means (raw means) and 95% CIs were calculated and reported along with the
range of the data. For lung homogenate, data was log transformed and then analyzed using a
mixed model as followed;
Yijk= µ +φi + ßj(i)+ tk + φtik + εijk
Where;
Yijk=(Ln transformed) observation of the ith group, the jth block within the ith group, and the kth
treatment
µ=overall constant
φi=fixed effect of the ith group
ßj(i)=random effect of the jth block within the ith group,
tk=fixed effect of the kth treatment
φtik=fixed interaction effect of the ith group and the kth treatment
εijk=residual

i = 1…number of group
j = 1…number of blocks within group
k = 1…number of treatments
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Back-transformed LS means (geometric means), standard errors of LS means and 95%
confidence intervals (CIs) were calculated. Least squares mean (LS mean) concentration was
used as an estimate of treatment mean. The significance level for fixed effects was set at 0.05.
The wet-to-dry ratios were summarized as arithmetic means, standard deviations (SDs), and
coefficient variations (CVs). Wet-to-dry ratios from both groups were compared statistically by
analysis of variance. Linear regression analysis was performed to test the linear association
between wet-to-dry ratio and drug raw concentration. Score data for health assessments were
summarized for animals in group 2 using frequency Tables.
Pharmacokinetic parameters were estimated using the WinNonlin software package
(Standard edition version 5.1, Pharsight Corporation, CA, USA). WinNonlin model 200 was used
for the noncompartmental analysis. Pharmacokinetic parameters were estimated using backtransformed LS menas derived from the naïve pooling from each sample point (8, 11).
Therefore, dispersion data of the PK parameters was not possible to be estimated. The area
under the concentration-time curve through 408 h post-dose, AUC0-408, area under the first
moment curve through 408 hours post-dose AUMC0-408, mean residence time (MRT), and the
terminal elimination half-life (t1/2) were estimated. The AUC0-408 was calculated by log-linear
trapezoidal rule, and λz was estimated with uniform weighting. The observed back-transformed
LS mean peak concentration (Cmax) and time of its occurrence (tmax) was obtained from
inspection of the back-transformed LSM concentration.

Results
All animals remained in good health throughout the acclimatization period. Two animals
in group 2 were euthanized 3 h after dosing with LPS. Animal 283 (from T04) had severe
respiratory distress, and animal 278 (from T02) was moribund. These animals were not
replaced. Consequently, the final number of animals in this group was 34. One animal in group
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1 (242 from T06) was affected with bronchopneumonia, and no lung samples were taken from
that animal. Animal 233 (from T02) had attitude score of 1 at the time of LPS administration.
The rest of the pigs remained in good health throughout the study as pre-defined in the IACUC
approved protocol. No adverse reactions or detrimental health effects were observed following
the administration of tulathromycin. Macroscopic lesions in the middle lobe of the group 2
animals were seen in the first 72 h after tulathromycin administration (Figure 5.1)
Animals in group 1 received an average tulathromycin dose of 2.63 mg /kg while animals
in group 2 received an average dose of 2.64 mg/kg.

Health assessment
Overall, the health assessment indicates that before starting the study all the animals
were considered clinically normal. At the time of tulathromycin administration (3 hours post-LPSEc administration) all the animals were clinically sick. At six hours after the LPS administration
two animals were severely affected, therefore they were euthanized as pre-established in the
protocols.

Attitude
At the time of tulathromycin administration only 2/36 animals had a score of 0. The rest
of the animals showed mild (13/36), moderate (19/36) and severe (2/36) changes. By six hours
after the administration of LPS-Ec (three hours after receiving the tulathromycin dose), all
animals were affected. Some were affected mildly (8/34) however most were moderately
affected (26/34).The animals recovered quickly, with over 80% receiving normal scores at nine
hours after receiving post LPS challenge (6 hours post-tulathromycin) and 100% of animals
were considered normal at all observations after 24h post-LPS.
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General condition
Three hours after receiving the LPS challenge (at the time of tulathromycin
administration), 25 out of 36 had mild changes in the general condition score while 2 out of 36
had and severe changes. The rest of the animals (25/36) were still considered to be generally
healthy. Six hours after LPS-Ec administration 6 out of 36 animals were mildly affected. All
animals were normal at ≥ 27 h after receiving the LPS-Ec dose.

Respiratory distress
Within one hour of LPS challenge, over 50% of the animals had mild or moderate clinical
signs of respiratory disease. Three hours after LPS challenge (at the time of tulathromycin
administration) 2 out of 36 animals had a score of 0. The rest of the animals showed mild
(17/36), moderate (16/36) and severe (1/36) changes. Six hours after LPS challenge (three
hours after tulathromycin administration), animals had mild (5/34), moderate (11/34) and severe
(18/34) respiratory distress. By 9 h after dosing LPS-Ec, >75% of the animals were clinically
normal with the remainder having only mild respiratory distress. All subsequent time points
showed all animals having normal respiration.
Health assessment scores are presented in Figure 5.2.

Plasma
Tulathromycin was rapidly absorbed in both groups. In group 1, tulathromycin plasma
Cmax was 630 ± 181 ng/mL (ranged from 272 to 1200 ng/mL) and occurred at 0.5 h (tmax). In
group 2, the plasma concentration vs. time (CT) profile was consistent with that of group 1
(AUC0-408 5765 and 5542 for group 1 and 2, respectively). The plasma Cmax was 286 ± 33 ng/mL
(ranged from 162 to 363 ng/mL) and occurred at 1 h (tmax) post administration of tulathromycin.
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In this group, the drug concentration range at 0.5 h was from 213 to 1190.The apparent t1/2 was
57.36 h.
The individual plasma concentrations of tulathromycin are included in Table 5.4 and
shown in Figure 5.3 and 5.4. Pharmacokinetic parameters are included in Table 5.5.
Lung homogenate
Tulathromycin rapidly and extensively distributed into the lung tissue (Table 5.6). In
group 1, the tulathromycin mean concentration (observed) in the middle lobe reached a
maximum of 2590 (ng/g) at 72 h post-dose, while in group 2 the Cmax was 2340 (ng/g) at 24 h
post-dose (Figure 5.3 and 5.4). In the caudal lobe, the Cmax for tulathromycin was 2590 ng/g at
24 h post-dose for group 1, while pigs from group 2 had a Cmax of 2010 ng/g at 72 h post-dose.
Overall, there were no statistically significant differences in caudal lobe concentrations between
the two dose groups (p=0.07) (Figure 5.3 and 5.4) but there were statistical differences at 24
(p<0.02) and 72 h (p=0.04). The partial AUC0-144 was 305000 and 254000 for group 1 and 2,
respectively. For the middle lobe, the concentration time profile was different (p<0.02) between
both dose groups, in particular at 6 h (p=0.03) and 72 h (p<0.01) post-tulathromycin
administration. The partial AUC0-144 was 300000 and 247000 for dose group 1 and 2,
respectively. There was not an association between the severity of the clinical signs and the
drug concentration in lung tissue. Tulathromycin was slowly eliminated from lung tissue and
persisted for a long period of time in all lobes from both experimental groups. At 408 h posttulathromycin administration, the lung:plasma ratio was > 300 for both lung lobes from both
groups. A summary of pharmacokinetic parameters is presented in Table 5.7.
Wet to dry ratios for lung tissue
Wet and dry ratio weights were determined for both lobes. Summarized data for the wet
to dry ratios are listed in Table 5.8. There were no statistical differences in the wet-to-dry ratios
in lung tissues between the two groups and lobes (p>0.05). No apparent trend could be
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observed over time. There was also no linear relationship (p>0.05) between LS mean
concentration and the wet-to-dry ratio (Figure 5.5 and 5.6).
Discussion
The CT profile of tulathromycin in LT and plasma was evaluated in both groups and
pharmacokinetic parameters were estimated in both matrices. The intra-tracheal administration
of LPS-Ec. triggers an acute inflammatory response. The LPS-Ec. model implemented in the
present study has been fully described elsewhere (Chapter 3). The intra-tracheal administration
of LPS-Ec. causes acute and reversible macroscopic and microscopic changes with remarkable
abnormal clinical signs. In the present study, consistent macroscopic lesions were observed in
both middle lobes within 72 h post-tulathromycin administration (75 h post-LPS-Ec). At the last 3
sampling times, no macroscopic lesions were observed in the post-LPS-Ec-challenged animals.
All animals received normal health assessment scores prior to the start of the study (except for
one animal (233) at -3 h) (Figure 5.2). Changes in clinical signs became evident 3 h after the
administration of the LPS- Ec challenge. Clinical scores and progression of clinical signs were
consistent with those reported previously (Chapter 3). Within 3 h after LPS-Ec. administration,
34 of the 36 animals were at least mildly affected, with 2 animals receiving an attitude score of
3. Those two animals were euthanatized. In the present study, maximal score changes were
recorded within 9 h post-LPS-Ec. administration. After that, the clinical score returned to normal.
Tulathromycin was administered to all animals in group 2, 3 h after the administration of the
challenge. The time of drug administration was selected because the manifestation of
respiratory distress might represent a deciding factor to initiate treatment under field conditions.
The time course of tulathromycin has been characterized in LT and plasma of pigs from
12 to 360 h and 0.5 to 360 h post-dose, respectively (5, 19). In the present study, the sampling
protocol was extended up to 408 h post-treatment administration. In addition, an earlier sample
time was included at 6 h post-tulathromycin administration. Another relevant difference in the
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experimental design compared to previous studies by

Benchaoui et al. (2004) (5) and

Nowakowski et al. (2004) (19) is that in the present study, two independent lung samples–one
from the middle and another from the caudal lobe–were taken for quantification of tulathromycin.
In previous studies, tulathromycin was quantified from a single representative lung tissue
sample.
Consistent with results published by Benchaoui et al. (2004) (5), tulathromycin was
rapidly absorbed (tmax 0.5 h) and had a prolonged elimination t1/2. In group 2, a plasma CT profile
consistent with that of group 1 was obtained (Table 5.5 and Figures 5.3 and 5.4). This indicates
that the intra-tracheal administration of LPS-Ec did not impact on the CT profile of the drug in
plasma.
Tulathromycin distributed extensively and rapidly into the lung, as previously reported in
pigs (5, 19), cattle (8, 19) and foals (27). In healthy animals (group 1), the LS mean CT profile in
both lung lobes was consistent (Table 5.6 and Figures 5.3 and 5.4). A similar observed LS
mean Cmax was observed at 24 h and 72 h post-administration for middle and caudal lobes,
respectively. In both lung lobes, the drug exposure was about similar. Tulathromycin was slowly
eliminated from both lung lobes with an apparent t1/2 of around 5.5 days (Table 5.7)
In the LPS-treated animal (group 2) there was a statistically significant change of the CT
in lung samples from the middle and caudal lobe of LPS-treated animals. In ML, lower drug
concentrations were obtained at 6 h (p=0.03) and 72 h (p<0.01). For the caudal lobe there were
statistical differences at 24 (p<0.02) and 72 h (p=0.04) post-tulathromycin administration.
Changes in the CT profile in lung tissue of LPS-treated animals are reflected in the
pharmacokinetic parameters, mainly in the AUC0-144. The LTgroup1: LTgroup2 ratio was 1.20 and
1.21 for the middle and caudal lobes, respectively. Despite the lower concentrations obtained at
some sampling times in LT of LPS-challenged animals, the overall exposure to tulathromycin in
both lung lobes was relatively high (AUC0-408 / AUC0-408

plasma

was > 78 fold). Also, high drug

concentrations persisted for a long period of time, with the LS mean concentration in LT >300
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times the plasma concentration 17 days after drug administration. The clinical significance of
changes in the CT profile and the pharmacokinetics parameters in LPS-challenged animals is
unknown.
Reports about drug concentration in pneumonic tissue are inconsistent. Concentrations
of danofloxacin in pneumonic craneo-ventral tissue were lower than those reported in normal
caudo-dorsal tissue (2). On the other hand, higher concentrations of oxytetracycline in
pneumonic than in normal calves have also been published (2). Many factors may determine
the rate and extent of drug accumulation during an inflammatory process, including the (i)
kinetics of the inflammatory cells in a particular tissue, (ii)

chronic vs. acute inflammatory

response (3, 12), (iii) site of infection (25), and (iv) type of drug (7, 17). The reason (s) for
changes in the tulathromycin CT profile and PK parameters in LT from the LPS-challenged
animals are unknown. Changes of the CT profile in LT cannot be attributed to changes in the
plasma CT profile (Figures 5.3 and 5.4). The systemic response to the LPS-Ec challenge may
trigger a hyper-dynamic state and local vascular changes, which may modify the disposition of
drugs within tissues (16). Despite the fact that this phenomenon might represent a potential
reason to explain the results obtained, this was not evaluated. Edema, as a consequence of the
inflammatory response, might have diluted the drug. This could also explain the lower
concentrations of the drug during the period of maximal tissue changes. Nevertheless, the wetto-dry ratio results do not support such hypothesis (Figures 5.5 and 5.6). Interestingly, there
were no statistical differences in the LS mean concentration value in pulmonary epithelial lining
fluid (PELF) between groups (Chapter 6).
It was reported that there is a considerable uptake and accumulation of tulthromycin in
neutrophils and macrophages (8, 24). There is published evidence indicating that some classes
of antimicrobials accumulate in inflammatory cells. The exposure to antigens cause the
accumulation of loaded cells at the site of infection/inflammation and triggers a rapid release of
intracellular drug after migration of the cell (3, 4, 6, 9, 10, 13, 14, 17, 21, 25). The inflammatory
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model used in the present study induces a remarkable influx of neutrophils and macrophages
into the middle lobe of the lung (Chapter 3). Consequently, it was expected that the significant
influx of neutrophils into the middle lobe would lead to a significantly larger local drug
accumulation. However, this was not reflected in the lung homogenate LS mean concentration
results. It could be possible that a more prolonged inflammatory response and/or multiple drug
administration might be required to detect a positive relationship between cellular infiltration and
the local drug accumulation as was reported for azithromycin (3). No significant differences
were detected between lung concentrations measured in infected and non-infected mice when
the dose was given at 48 or 72 h after delivery of the challenge or sterile broth. In contrast, a 4to 7-fold increase in lung concentration was observed in lungs taken from infected animals
dosed at 96 or 120 h after challenge (3).
In conclusion, in both healthy pigs and LPS-challenged animals, the distribution of the
drug into the lungs was rapid and persisted at relatively high levels for 17 days postadministration. The distribution of the drug within the lung seems to be homogenous, at least
between the middle and caudal lobes within dosing groups. The LS mean CT profile of the drug
and pharmacokinetic parameters in 2 different lung areas (middle and caudal lobe) were
consistent within the groups. The concentration of tulathromycin was significantly lower in the
middle lobe after the intratracheal administration of LPS-E- coli. The clinical significance of the
change in the CT profile is unknown.
Two additional pieces of information certainly may help to fully unravel the unique
pharmacokinetic profile of tulathromycin in lung tissue, namely (i) the evaluation of the impact of
chronic inflammation on the pulmonary pharmacokinetics of the drug, and (ii) the influence of
the time of drug administration with respect to the pathological stage on the CT profile of the
drug in lung tissue.
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Appendix
Table 5.1. Clinical score assessment used for evaluation of animals challenged intra-tracheally with LPS-Ec.
Observation

Attitude
(depression)

Score
0
1

2

3

0
Respiratory
Distress

1
2
3

General
Condition
(includes appetite
evaluation)

0
1
2
3

Clinical Description
Normal – Pig is up and active when entering the room or when approaching.
Mild depression – Pig is slightly inactive, but gets up after being approached; pig moves slowly and
appears lethargic; shows some interest in food and social interaction, but stays active only for a
few minutes; animal may appear gaunt and have a rough coat.
Moderate depression – Pig shows pronounced inactivity and gets up only after light back pressure;
displays little or no interest in food and/or social interaction; tends to lie down almost immediately
and/or stands with head down; noticeably gaunt and coat is rough; staggers and appears slightly
uncoordinated at the walk.
Severe depression/moribund – Pig is moribund, unresponsive to stimuli, unable to get up or does
so with difficulty; shows no interest in surroundings, food, or social interaction; appears anxious;
should be euthanized for humane reasons.
None – Respiratory movements are subtle, superficial, and can be observed only when animal is
quietly lying down.
Mild – Respiratory movements are obvious and predominantly abdominal.
Moderate – Respiratory movements are exaggerated, entirely abdominal, and labored.
Severe – Respiration is very labored and entirely abdominal; pig breaths through mouth
(continuously or intermittently); nose and/or ears are cyanotic; should be euthanized for humane
reasons.
Clinically normal appearing animal
Slightly abnormal condition
Moderately abnormal condition
Severely abnormal condition

141

Table 5.2. Sampling (tissue) and treatment design implemented for healthy pigs and animals challenged intra-tracheally with LPS-Ec
3 h prior to tulathromycin administration.
Days

-1

0

1

2

3

4–5

6

7–9

10

11–16

17

48

72

96–120

144

168–216

240

264–384

408

X

XN

h
T01

NA
X

-3
LPS

-2
X

0
XT

3
X

6
XN

24

T02

X

LPS

X

XT

X

X

XN

T03

X

LPS

X

XT

X

X

X

X

XN

T04

X

LPS

X

XT

X

X

X

X

X

X

XN

T05

X

LPS

X

XT

X

X

X

X

X

X

X

T06
XT
XN
X
LPS
X
X
X
X
X
X
X
X
X
X
X
X–Clinical observation taken (evaluations from 96 h were performed daily); T–tulathromycin administration; LPS:LPS-Ec dose
administration; N–Necropsy performed. For animals in dose group 1, evaluations were performed as with dose group 2 but starting at
0 h.
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Table 5.3. Blood sampling design for pigs administered a single i.m. injection of tulathromycin at
2.5 mg/kg body weight.
Treatment group T01 T02 T03 T04 T05 T06
05
4
32
80 169 264
Times blood
1
8
48
96 192 312
sampled (h)
2
10
56 120 216 360
6
24
72 144 240 408
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Table 5.4. Summary of concentration (ng/mL) of tulathromycin in plasma from pigs treated with
a single i.m. injection of tulathromycin at 2.5 mg/kg body weight.

Dose Group
1

2

Treatment Group
(h)
T01 (6)

n

h

Raw Mean

95% CIs

Range

6

0.5
1
2
4
6
8
10
24
32
48
56
72
80
96
120
144
168
192
216
240
264
312
360
408
0.5
1
2
4
6
8
10
24
32
48
56
72

630
275
203
149
266
149
115
61.9
37.6
25.4
22.6
22.5
9.10
10.8
6.99
6.25
3.65
2.74
2.14
1.82
1.63
1.74
1.21
1.36
269
286
212
204
247
85
87.7
86.8
35.6
25.7
17.5
19.8

267-992
192-358
161-244
128-170
173-360
121-176
90.0-140
45.2-78.6
30.9-44.3
19.6-31.2
17.7-27.5
20.8-24.2
8.17-10.0
9.77-11.8
5.18-8.81
5.13-7.38
2.70-4.60
2.12-3.36
1.53-2.74
1.33-2.30
1.28-1.99
1.39-2.09
1.07-1.35
0.90-1.82
851-529
219-352
137-288
89.7-317
126-367
64.0-106
72.3-103
67.8-106
30.1-41.2
21.4-30.0
15.7-19.3
16.9-22.7

272–1200
187–448
153–273
161–426
114–187
115–210
88.3–170
42.5–99.3
29.6–48.1
18.3–36.5
19.2–34.6
19.8–24.7
7.74–11.1
9.16–12.6
5.46–11.3
4.47–8.48
2.29–5.75
1.52–3.53
1.16–2.99
1.11–2.65
1.13–2.49
1.04–2.53
1–1.79
0.8–2.27
213–1190
162–363
117–375
80.6–436
131–460
49.1–108
58–100
61.4–109
23.4–42.6
20.1–33.9
14.5–20.2
14.1–23.6

T02 (24)

6

T03 (72)

6

T04 (144)

6

T05 (240)

6

T06 (408)

6

T01 (6)

6

T02 (24)

5

T03 (72)

6
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Table 5.4. Continued
Dose Group

Treatment Group
(h)
T04 (144)

T05 (240)

n

h

Raw Mean

95% CIs

Range

5

80
96
120
144
168
192
216
240

11.2
9.65
6.70
7.67
3.17
2.47
2.41
2.19

8.06-14.2
8.41-10.9
5.49-7.91
6.61-8.72
2.65-3.68
2.01-2.93
2.10-2.72
1.77-2.61

7.95–16.3
8.12–11.2
4.96–8
5.82–8.8
2.44–3.97
1.9 –.23
1.92–2.86
1.51–2.75

6
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Table 5.5. Summary of plasma pharmacokinetic parameters in pigs treated with a single i.m.
injection of tulathromycin at 2.5 mg/kg body weight.
Pharmacokinetic
parameter*

Treatment group
Group 1

Group 2

HL_Lambda_z (h)

54.4

57.3

Tmax (h)

0.50

0.50

Cmax (ng/mL)

630

286

Clast (ng/mL)

1.31

1.32

AUClast-pred (h*ng/mL)

5760

5540

AUCinf -obs(h*ng/mL)

5780

5560

288000

282000

51.4

52.5

AUMClast (h*h*ng/mL)
MRTINF_pred (h)

* Dispersion data of the PK parameters are not presented because PK parameters were
estimated based means derived from the naïve pooling from each sample point.
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Table 5.6. Summary of the LS mean concentration (ng/g) of tulathromycin in LT from pigs treated with a single i.m. injection of
tulathromycin at 2.5 mg/kg body weight.
Lung Section
Middle Lobe

Treatment (h)
T01 (6)
T02 (24)
T03 (72)
T04 (144)
T05 (240)
T06 (408)

Caudal Lobe

T01 (6)
T02 (24)
T03 (72)
T04 (144)
T05 (240)
T06 (408)

†

Dose
Group
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2

n

LS Mean†

95% CIs†

Range#

6
6
6
5
6
6
6
5
6
6
5
6
6
6
6
5
6
6
6
5
6
6
5
6

1660
1200
2380
2340
2590
1750
1260
1380
884
828
357
330
1740
1740
2590
1670
2530
2010
1310
1580
735
837
464
388

1370-1950
992-1410
1960-2790
1900-2790
2140-3040
1450-2060
1040-1480
1120-1640
730-1040
670-986
289-426
273-388
1470-2010
1470-2000
2190-2990
1380-1950
2140-2930
1700-2330
1110-1510
1320-1860
621-849
707-967
385-543
327-448

1370–2530
971–1840
1980–3480
1740–2850
1880–3330
1320–2360
974–1650
1160–1830
765–1000
665–961
237–431
215–469
1390–2270
1140–2400
2170–3570
1040–1990
1950–2960
1660–2200
1040–1610
1290–2090
491–890
745–1040
399–552
307–588

Back-transformed data for reporting, # correspond to raw drug concentrations
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Table 5.7. Summary of the pharmacokinetic parameters of tulathromycin in LT in pigs treated with a single i.m. injection of
tulathromycin at 2.5 mg/kg body weight.
Treatment Group
Pharmacokinetic
parameter*

Group 1

Group 2

Middle

Caudal

Middle

Caudal

lobe

lobe

lobe

lobe

HL_Lambda_z (h)

143

142

137

137

Tmax (h)

72.0

24.0

24.0

72.0

Cmax (ng/mL)

2590

2590

2340

2010

Clast (ng/mL)

357

464

330

388

AUClast(h*ng/mL)

506000

504000

450000

473000

AUCinf_obs (h*ng/mL)

580000

6000000

515000

550000

68600000

68200000

63800000

69100000

MRTINF_pred (h)

197

203

202

209

AUC0-408 LT:Plasma ratio

87.4

90.9

78.1

85.3

AUMClast(h*hr*ug/mL)

*Dispersion data of the PK parameters are not presented because PK parameters were estimated based on least square means
derived from the naïve pooling from each sample point
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Table 5.8. Wet-to-dry weight ratios of lung tissue from healthy pigs and animals challenged
intra-tracheally with LPS-Ec 3 h prior to tulathromycin administration.
Lobe

Treatment (h) Group Mean SD

Middle

T01 (6)

T02 (24)

T03 (72)

T04 (144)

T05 (240)

T06 (408)

Caudal T01 (6)

T02 (24)

T03 (72)

T04 (144)

T05 (240)

T06 (408)

%CV

1

5.77

0.28 5.00

2

5.58

0.11 2.06

1

5.64

1.63 28.9

2

5.77

0.07 1.35

1

6.27

0.80 12.8

2

5.89

0.35 6.01

1

6.31

1.07 16.9

2

5.65

0.21 3.88

1

5.68

0.05 1.00

2

5.75

0.12 2.11

1

5.91

1.02 17.2

2

5.49

0.70 12.9

1

5.63

0.30 5.33

2

5.59

0.10 1.89

1

6.34

1.56 24.6

2

5.66

0.20 3.53

1

5.55

0.11 2.04

2

5.78

0.14 2.43

1

5.53

0.14 2.57

2

5.45

0.08 1.60

1

5.37

0.09 1.68

2

5.44

0.09 1.66

1

5.59

0.58 10.5

2

5.54

0.24 4.34

No statistical differences were found between lobes
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Figure 5-1 Lung gross changes induced by intra-tracheal administration of LPS Ec.
at 24h post-challenge (arrows point at abnormal gross areas).
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Figure 5.2. Clinical score assessment results from pigs challenged intra-tracheally with LPS-Ec. (A) Attitude score results. (B)
Respiratory distress score results. For both scores, results beyond 96 h were not included because all animals had a normal score.
Clinical assessment scores for general health are not graphically presented. For these scores, mild changes were recorded in ~25%
of animals, only between -3 and 6 h post LPS.
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Figure 5.3. Least squares mean concentration (±SE) of tulathromycin in LT (ng/g) and mean
concentration (±SE) in plasma (ng/mL) from pigs administered a single i.m. injection of
tulathromycin at 2.5 mg/kg body weight. Overall, there were statistical differences between
middle lobe drug concentrations from both dose groups (p<0.02) but not for caudal lobe
(p=0.07).

152

3000

Concentration (ng/mL)

2500

2000

1500

1000

500

0
0

10

20

30

40

50

60

70

80

90

100 110 120 130 140

Time (h)
Dose Group 1 ML

Dose Group 1 CL

Plasma Dose Group 1

Dose Group 2 ML

Dose Group 2 CL

Plasma Dose Group 2

Figure 5.4. Least squares mean concentration (±SE) of tulathromycin in LT (ng/g) and mean
concentration (±SE) in plasma (ng/mL) from pigs administered a single i.m. injection of
tulathromycin at 2.5 mg/kg body weight. For clarity, the small graph depicts tulathromycin
concentration 0–72 h post administration. ML: correspond to middle lobe and CL, caudal lobe.
For middle lobe there were statistical differences at 6 h (p=0.03) and 72 h (p<0.01). For caudal
lobe there are statistical differences at 24 (p<0.02) and 72 h (p=0.04).
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Figure 5.5. Linear regression concentration of tulathromycin in lung tissue vs. wet to dry ratio for
middle lobe (R2= 0.08).
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Figure 5-6. Linear regression concentration of tulathromycin in lung tissue vs. wet to dry ratio for
caudal lobe (R2= 0.10).
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Chapter 6:

PULMONARY PHARMACOKINETICS OF TULATHROMYCIN IN
SWINE: INTRA-AIRWAYS COMPARTMENTS
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Abstract
Knowledge of drug concentration in the intra-airway compartments can provide valuable
information for treatment. The objective of this study was to assess the pharmacokinetics of
tulathromycin in pulmonary and bronchial epithelial lining fluid (PELF and BELF) from pigs.
Clinically healthy Duroc x Landrace pigs were allocated to two groups of 36 animals each. All
animals were treated with tulathromycin (2.5 mg/kg). Animals in group 2 were also challenged
intra-tracheally with lipopolysaccharide from Escherichia coli 3 h prior to tulathromycin
administration. Both PELF and BELF were harvested using bronchoalveolar lavage fluid and
bronchial microsampling probes, respectively. Samples were taken for 17 days posttulathromycin administration. No statistical differences in the concentration of tulathromycin
were observed in PELF between groups. The concentration vs. time profile in BELF was
evaluated only in Group 1. Tulathromycin distributed rapidly and extensively into the airway
compartments of both groups. Area under the concentration-time curve through 408 h post-dose
was 522000, 348000, and 1290000 for PELFGroup-1, PELFGroup-2, and BELFGroup-1, respectively.
The PELF:plasma concentration ratio ranged from 29.6 to 271 and 6.39 to 194 for Group 1 and
2, respectively. The BELF:plasma concentration ratio range was 2.69–1615 for Group 1. The
drug was slowly eliminated from PELF and BELF, with apparent terminal elimination half-life
values of 87.3, 108, and 203 h for PELFGroup-1, PELFGroup-2, and BELF, respectively. This is the
first study describing the disposition of tulathromycin in both BELF and PELF in pigs.
Tulathromycin not only distributed rapidly into intra-airway compartments at relatively high
concentrations but also resided in the airway lining fluid for a long time (>4 days).

Keywords: tulathromycin, antimicrobial, pig, bronchial epithelial lining fluid, lung
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Introduction
Drug concentrations at the site of infection are clinically relevant (15), as it is broadly
accepted that biophase drug kinetics is the primary controller in the antimicrobial response (1517, 37). Tulathromycin is a macrolide antimicrobial that has shown an extraordinary efficacy to
treat and prevent bovine and swine respiratory disease when used following labeled indications.
The efficacy of this drug to treat the labeled conditions may be a consequence of an extensive,
rapid, and prolonged accumulation of the drug in the lung tissue. Previous studies characterized
the pharmacokinetics of tulathromycin using lung homogenate from pigs and cattle (4, 42).
However, little is known about the accumulation of this drug in the different pulmonary
compartments. In fact, there is no information about the intra-airway concentration vs. time
profile of tulathromycin in pigs. Recently, Cox et al. (2010) described the concentration vs. time
profile of tulathromycin in not only lung homogenate but also pulmonary epithelial lining fluid
(PELF) and bronchoalveolar lavage (BAL) cells. Consistent with results observed in lung
homogenate samples, tulathromycin also extensively accumulated in the intra-airway
compartments both intra-and extra-cellularly.
The intra-airway compartment represents the primary niche for bacterial contamination
and infection (14, 18). Consequently, information about target site drug penetration and kinetics
in the airway epithelial lining fluid would provide valuable evidence to aid in understanding the
lung accumulation and positive clinical outcomes of tulathromycin. Due to the anatomical
location of lungs, its conformation, and function, veterinary scientists face a unique challenge in
studying drug-lung pharmacokinetics. This may explain why most lung pharmacokinetic studies
are based only on lung homogenate concentrations rather than in airways and alveolar surface
fluid.
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The objective of this study was to assess the pharmacokinetics of tulathromycin in the
intra-airway compartments in healthy pigs and pigs challenged intra-tracheally with
lipopolysaccharide Escherichia coli (LPS-Ec) during a period between 0 to 408 h.

Material and methods
Animals and housing
Animals and housing conditions were fully described in part 1 of the study (chapter 5).
Study design
The full study design was fully described in part 1 of the study (chapter 5). Briefly, 72
healthy animals were randomly allocated into six treatment groups with six experimental
animals per treatment group according to a split plot design. Each group was scheduled for
euthanasia at 6, 24, 72, 144, 240, or 408 h post-tulathromycin administration. Of the 72
experimental animals, 36 were treated with an intra-tracheal inoculum of LPS-Ec 3 h prior to the
administration of tulathromycin. On study day 0, all animals were administered one i.m. injection
of tulathromycin (Draxxin Injectable Solution, Pfizer Animal Health, New York, NY) at 2.5
mg/kg in the neck.

Bronchial epithelial lining fluid and pulmonary epithelial lining fluid

Bronchial epithelial lining fluid.
Bronchial epithelial lining fluid (BELF) samples were taken from all animals in group 1
and animals scheduled to be euthanized at 24 h post-tulathromycin administration in group 2.
Bronchial epithelial lining fluid was gathered from each animal using bronchial micro-sampling
(BMS) probes (Model BC-402C Olympus, Tokyo, Japan) as described previously (29, 32, 33,
60). Briefly, immediately after euthanasia, the trachea was exposed and a flexible fiber-optic
endoscope (Olympus, model XP-10) and a BMS probe were inserted into the trachea and
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directed into the right middle lobe following the bronchi until resistance was met. The sampling
portion of the BMS probe was uncovered from the protective sheath and was visually placed in
contact with the bronchus wall for approximately 20 sec. The sample portion of the probe was
pulled back into the sheath before removing the BMS prove from the bronchoscope. The cotton
tip (sample portion) was trimmed off from the rest of the sampling device, collected into a
polypropylene tube, transported on wet ice (~0 °C) and stored at -20 °C until analysis. After the
first sampling procedure, the fiberscope was kept in place, and the sampling procedure was
repeated two additional times using new BMS probes each time. The three sampling probes
were pooled into a common polypropylene tube. Thus, samples harvested from the three
sampling probes from each animal at each sampling time represented a single (pooled) BELF
sample. The fluid volume gathered from each probe was estimated by weight as previously
reported (29, 32, 33, 60).

Pulmonary epithelial lining fluid.
Following BMS procedures, PELF was collected from each animal by BAL. Briefly, one
of the bronchi was obliterated using hemostatic forceps. Thus, PELF was harvested from the
contralateral lung. Lung was kept in a vertical position, and approximately 50 mL of 0.9% saline
was instigated through the trachea into the bronchus using a disposable pipette, assuring
complete distribution across the lung. Recovery of BALF into 50 mL polypropylene tubes was
accomplished by gentle aspiration with a disposable pipette. Immediately after recovery of BAL
fluid, the sample was centrifuged at 450 RCF for 10 min at ~4 °C for separation of the cell
fraction, and then the cell-free BALF fraction was gently decanted into a polypropylene tube (2,
12, 31). Estimation of PELF volume was performed as previously described, quantifying urea as
a dilution factor (47).
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BAL fluid cell fractions

Cells isolated from BAL fluid were washed twice with 5 mL of 0.9% saline. Upon addition
of the first 5 mL of wash solution, a 20 L aliquot of the re-suspended material was transferred
to glass slides (in duplicate) and stained with Diff-Quick solution for cell differential counting.
Following the second wash, the cell pellet was re-suspended in 5 mL of 0.9% saline for shipping
and processing. Cells were processed as quickly as possible to preserve their integrity.
Differential cell population count was performed by a pathologist (DGT) by microscopy. A
predefined-cell population proportion criterion was set at > 90% of either neutrophils or
macrophages. Thus, a minimum of > 90% of a single cell population was required in order to
use a reference intracellular volume to express drug concentration in terms of intracellular
concentration.

Intra-lower respiratory airways and alveolar inflammatory cells
The total number of cells harvested by the BAL fluid was counted using an automatic
method as implemented by the ADVIA® 120 counter (Advia® 120 hematology system, Deerfiel,
IL, USA). Then, the samples were adjusted to 106 cells/mL with 0.9% saline. After normalization
of the number of cells, the samples were sonicated. The resulting solution was analyzed for
concentration of tulathromycin.
Serum samples
Blood (for serum) samples were collected from all animals at necropsy at 6, 24, 72, 144,
240, or 408 h post-tulathromycin administration.

Analytical methods

All the matrix samples were analyzed for tulathromycin content by high performance
liquid chromatography with tandem mass spectrometry detection following procedures
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described by Galer et al. (2004) (23) and Cox et al. (2010) (12) Roxithromycin was used as an
internal standard (50).

Bronchial epithelial lining fluid
Briefly, the method for extraction of tulathromycin from the probe began with introduction
of 2 mL of 20 mM pH 4 ammonium acetate:acetonitrile (50:50 v:v) into the tube containing the
sampling probe. The sample was vortexed for approximately 1 min and then sonicated for 2
min. A 50 µL sub-sample aliquot was spiked with 200 µL of roxithromycin (25 ng/mL) into a
glass tube, vortexed for 1 min and centrifuged at ~1500 RCF for 10 min. A supernatant aliquot
(~200 µL) was transferred into a glass vial, and 5 µL was injected into the system for analysis.
The calibration range was 1.0 to 500 ng/mL (R2 > 0.99) using nine calibration standards. The
intra-run bias for the calibration standards ranged from -10.0 to 12.0%. Study samples were
analyzed in one run. Three quality control samples (2.5, 25 and 100 ng/mL) were included in the
analysis. The bias in the assays of the quality control samples ranged from -14.3 to 9.2%.

Cell-free BAL fluid
A 100 µL volume of the BAL supernatant was mixed with 400 µL of acetonitrile
containing roxithromycin. After centrifugation, 390 µL of supernatant was transferred to another
tube and evaporated under nitrogen gas. The sample was then reconstituted with 100 µL of 20
mM pH 4 ammonium acetate:acetonitrile (80:20 v:v), and a 10 uL aliquot was injected into the
chromatographic system. The calibration range was 1.0 to 500 ng/mL (R2 > 0.99) using nine
calibration standards. The intra-run coefficients of variation for standards ranged from 0.1 to
14.6% and the intra-run bias ranged from -5.6 to 11.0%. All samples were analyzed in one run,
and the intra-run coefficients of variation for quality controls at 3, 30, and 300 ng/mL ranged
from 10.0 to 14.4%. The intra-run bias in the assays of the quality control samples ranged from 7.3 to -1.3%.
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Urea assays
Serum and cell-free BAL urea concentrations were measured using an LC-MS/MS as
previously described (12). Cell-free BAL fluid supernatant (2 µL) was injected onto a
chromatographic system. Chromatography was accomplished with a BEH C18, 1.7 µm, 2.1 x 50
mm column (Waters Corp., Milford, MA, USA) with gradient elution. For the gradient elution,
mobile phase containing 100%, 0.1% formic acid in water was used initially (0–0.2 min postinjection). Then, a linear gradient elution from 0 to 80% methanol and 20% formic acid (0.1%)
was implemented over 4 min. A flow rate of 0.250 µL/min was applied. The retention time for
urea was approximately 1 min. Detection occurred via a Sciex API 4000 mass spectrometer
using an electrospray ionization source, and positive ions were monitored with precursor →
product ion pairs of 61 → 44. For both matrices, calibration occurred over a range of 0.005 to 1
mg/dL (R2 > 0.99) using eight calibration standards, and three quality control samples (0.015,
0.03, and 0.3 mg/dL) were included in each analytical run. All assays for urea in both matrices
were performed in one analytical run. For the serum quality control samples, the intra-run
coefficients of variation ranged from 2.6 to 10.1%, and the intra-run biases ranged from -2.0 to
4.7%. For the BAL fluid quality control samples, the intra-run coefficients of variation ranged
from 1.9 to 7.6%, and the intra-run biases ranged from 0.3 to 6.0%.

Biometrical and pharmacokinetic analyses
To analyze BELF, PELF, and cellular concentrations, A log transformation was applied
to the concentration data for all tissues prior to analysis. Least squares means were estimated
using a mixed model as followed;
Yijk= µ +φi + ßj(i)+ tk + φtik + εijk
Where;
Yijk=(Ln transformed) observation of the ith group, the jth block within the ith Dose Group, and the
kth treatment
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µ=overall constant
φi=fixed effect of the ith group
ßj(i)=random effect of the jth block within the ith group,
tk=fixed effect of the kth treatment
φtik=fixed interaction effect of the ith group and the kth treatment
εijk=residual

i = 1…number of roup
j = 1…number of blocks within group
k = 1…number of treatments

Least squared means and standard errors of LS means were estimated and 95% CIs
were constructed. Back-transformed LS means (geometric means) and CIs for each treatment
and group were reported. Least squares mean (LS mean) concentration was used as an
estimate of treatment means. The groups were tested for significant differences for fixed effects
at the  = 0.05 level, indicating that p values  0.05 showed a significant difference for the
effect. Drug concentrations were expressed in ng/mL unless stated differently.
Pharmacokinetic parameters were estimated using WinNonlin software (Standard edn.
version 5.1, Pharsight Corporation, CA, USA). WinNonlin model 200 was used for the noncompartmental analysis. Pharmacokinietic parameters were estimated using LSM derived from
the naïve pooling from each sample point [13]. Therefore, dispersion data of the PK parameters
was not possible to be estimated. Area under the concentration-time curve through 408 h postdose (AUC0-408), area under the concentration-first moment time curve through 408 h post-dose
(AUMC0-408), mean residence time (MRT), and the terminal elimination half-life (t1/2) were
estimated. The AUC0-408 was calculated by the log-linear trapezoidal rule, and λz was estimated
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with uniform weighting. The observed peak LS mean concentration (Cmax) and time of its
occurrence (tmax) were obtained from inspection of the LSM concentration.
Results
All animals remained in good health throughout the acclimatization and study periods.
One animal (No. 242 from the 408 h group 1) was determined to be affected with
bronchopneumonia and no samples were collected. Two animals in group 2 were euthanized.
Animal 283 (from the 144 h treatment group) had severe respiratory distress and animal 278
(from the 24 h group) was moribund after the administration of LPS-Ec. No adverse reactions or
detrimental health effects were observed following the administration of tulathromycin. The
overall average dose of tulathromycin administered was 2.64 mg/kg which represents an over
dose of 5.4%.
BELF
In group 1, tulathromycin was quantified during a period of 17 days post-administration.
The maximal LS mean concentration was 5040 ± 801 at 72 h post-administration of the drug.
After 72 h, the drug concentration declined slowly (apparent t1/2 values 213 h). At 17 days (408
h) post administration, the concentration of the drug was still relatively high (1680 ± 291). LS
mean concentration results are presented in Table 1. The concentration vs. time profile is
shown in Figure 6-1. The concentration in BELF from LPS-Ec-challenged animals was
evaluated only at one sampling point (24 h post-tulathromycin administration). The LS mean
concentration obtained was consistent with concentrations obtained at the same sampling time
in group 1 (LS mean ± SE, 3240 ± 561 in group 2 vs. 3570 ± 567 in group 1) (p > 0.05).

Cell-free fraction of BAL fluid (PELF)
Tulathromycin LS mean concentrations were evaluated in PELF from both groups (Fig. 1
and Table 1). A summary of the LS mean concentration results are presented in Table 1. The
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summary of pharmacokinetic parameters is presented in Table 2. In group 1, the maximum LS
mean concentration (LS mean ± SE, 7890 ± 2680) was observed at 6 h post-tulathromycin
administration. In group 2, the maximal LS mean (± SE) concentration was 2580 ± 951 at 24 h.
After the peak tulathromycin concentration, it declined slowly with a terminal half-life of 87 and
108 h in PELFGroup-1 and PELFGroup-2 respectively.
Differential counts
Smear samples from BAL fluid from both groups were evaluated. In group 1, most of the
cells counted belonged to the epithelial cell population. In 9/35 samples, macrophages were
identified. However, none of the samples evaluated reached the minimum predefined cell
population proportion criteria (> 90% of macrophages). In group 2, the cell population
proportions differed from the trend observed in group 1. During the first 27 h after challenge
administration

(24

h

post-tulathromycin

administration),

neutrophils

were

the

most

representative cell population observed. The cell population proportion observed was not
consistent within the treatment groups nor across the 27 h post-LPS-Ec administration. In
addition, none of the samples evaluated reached the minimum predefined cell population
proportion criteria (> 90% of neutrophils). After 27 h post-LPS-Ec administration, the cell
population proportion was consistent. However, the main cell population counted was based on
epithelial cells.
BAL fluid cells concentration
The concentration vs. time profile of tulathromycin in 106 cells is presented in Figure 6-2.
There was a significant difference in tulathromycin concentrations between animals in group 1
and group 2. The concentration vs. time profile was similar in both groups during the first 72 h
post dosing. The maximum LS mean concentration was 13.3 and 14.7 ng/mL for group 1 and 2,
respectively. After the peak concentration (72 h), tulathromycin declined more slowly in group 2
than group 1.
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Discussion
Several studies have shown that tulathromycin exerts a positive role in the treatment and
control of bovine and swine respiratory disease (28, 40, 43, 56, 57). An important reason for this
is the extraordinary lung selectivity and unique concentration vs. time profile of this triamilide in
pulmonary tissue (4, 16, 42). Predictions about antibacterial efficacy are generally performed
using serum/plasma drug concentrations as a surrogate for the drug concentration at the site of
infection. However, the actual concentration-time profile at some sites of infection could differ
from that in serum or plasma. This caveat puts into question the value of serum/plasma
concentration as a surrogate for peripheral drug concentration for certain antimicrobials (15, 38).
This holds true in particular for macrolides, including tulathromycin, for the treatment of
pneumonia since plasma concentration does not mirror tissue concentration (4, 12, 41, 58). In
respiratory conditions, the target tissue is the lung. In particular the extracellular fluid, like the
epithelial lining fluid that covers the route of entry and colonization of microorganisms
associated with pneumonia. Technical complications limit the use of most techniques to take
appropriate samples from potential infection sites in the intra- and extra-pulmonary airways and
lung tissue. Consequently, the characterization of the concentration vs. time profile of
tulathromycin in lung tissue from pigs, and other antimicrobials in different species, has been
accomplished mainly by homogenizing lung tissue. However, total antibiotic concentration
measurements from tissue homogenate cannot be routinely considered as valid, and results or
interpretations based on them may be misleading. The main reason for this argument is that
lung homogenate is a hybrid heterogeneous sample, since it encompasses multiple
compartments (e.g. intravascular, extracellular, and intracellular). For most microorganisms, the
actual target biophase is the interstitial space fluid; therefore, effective concentrations might be
under or overestimated (39).
Even though the concentration of tulathromycin in BELF from pigs has been previously
reported (Chapter 4), this is the first study describing the concentration vs. time profile of
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tulathromycin in BELF and PELF in pigs. Bronchial epithelial lining fluid was defined in this study
and others as the sample obtained from the secondary bronchi at the middle lobe by the BMS
probe (29, 32, 33, 60). Pulmonary epithelial lining fluid represented the cell-free fluid obtained
from BALF after normalization with urea (47). Some studies available in the literature consider
the concentrations of the drug as a result of this technique as drug concentration in alveolar
epithelial lining fluid. However, it is important to recognize that the epithelial lining fluid,
harvested by BAL fluid, represents a pooled lining fluid that covers the entire lower airway
compartments and the alveolar lining fluid. Thus, the epithelial lining fluid obtained by BAL fluid
is considered in the present study as PELF, and the concentration of tulathromycin in PELF
represents lower intra-airway and alveolar composite concentrations.
As reported for lung tissue samples (Benchaoui et al. 2004) (4), tulathromycin
concentrations were notably high in the intra-airway compartment, BELF, and PELF in both
groups (Table 1). The AUC0-408 ratio of PELF-plasma and BELF-plasma was 90 and 223,
respectively. The extraordinary clinical outcome of the drug after a single administration may be
explained by not only the magnitude of drug concentration, but also the long persistence of the
drug in the intra-airway compartments (5, 28, 40).
The concentration of tulathromycin in the intra-airway compartments far exceeded
plasma concentrations (Table 1). The basic nature of the drug and a limited degree of ionization
at physiological pH (triamilide with a pKa range of 8.49–9.80) represent features that favor the
distribution of the drug into extra-vascular compartments (Benchaoui et al. 2004) (4).
Nevertheless, the exact mechanism of drug tissue distribution is unknown. The drug penetrated
rapidly into the airways, but concentration declined slowly. Also, the drug concentration ratio
PELF:plasma and BELF:plasma change in a time and concentration dependent manner
following drug administration (ratio range 29.6–271 and 2.69–1615 for PELF:plasma and
BELF:plasma, respectively) (Table 1). This result might indicate that different factors intervene
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in the process of movement of the drug in and out between the plasma and the airway
compartments.
A common misconception is that the lung is a uniform matrix, but it is important to
remark that there are relevant histological and physiological differences (regional blood flow,
heterogeneous rate of formation, absorption, and clearance and chemical composition of the
airway surface liquid, etc.) among lung sections. These differences may account for variability in
the local pharmacokinetics of the drug at different intra-pulmonary levels (7). The equilibrium
between compartments does not occur instantaneously, and the shape of the concentrationtime profile in either compartment can therefore be markedly different (36). It is evident in Figure
6-1 that the shapes of the concentration-time profiles of tulathromycin in PELF and BELF in
group 1 differ from each other. Tulathromycin in PELF reached the maximum concentration at 6
h post-administration of the drug, while the BELF Cmax was later (72 h post-tulathromycin
administration) and lower (LS mean ± SE 5040 ± 801.8 vs. 7890 ± 2680). The decline of the
drug in BELF took longer than in PELF (half-life of terminal phase; 213 h for BELF vs. 87 h for
PELF). The reasons for the unequal penetration and removal rate and extent of accumulation of
tulathromycin from PELF and BELF are not clear. However, the differences observed in the rate
of accumulation in PELF and BELF may be due to the combination of at least three factors: (i)
unequal surface areas (larger for PELF) (ii) differential histological features, and (iii) differences
in blood flow (44). The alveolar region receives nearly the entire proportion of the cardiac output
by pulmonary circulation. On the contrary, the airways receive approximately 1% of the cardiac
output (13, 22). Unequal removal of the drug from the intra-airways and alveolar compartment
might be dictated by differences in epithelial permeability and absorptive capacity (8, 46),
metachronous beating of cilia (10, 11, 45, 46), heterogeneous binding to different
intrapulmonary components (mucus phospholipids), unequal release of the drug (19, 25) and
drug structural modifications (34). Undoubtedly, further work is needed to identify the
intervenient factor(s) accounting for differences in the intrapulmonary compartment.
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The concentration of tulathromycin in BELF from animals challenged intra-tracheally was
evaluated only at one sampling point (24 h post administration). The reason for this was that
only preliminary reference information from this group was desired. Results, at 24 h posttulathromycin administration, were consistent with concentrations obtained at the same
sampling time in group 1 (Table 2).
The concentration vs. time profile of tulathromycin in PELF in group 2 differed from group 1.
This was evident during the during the first 24 h post-tulathromycin administration. As stated
earlier, the peak concentration of PELF from group 1 (LS mean ± SE, 7890 ± 2680) was at 6 h
post-tulathromycin administration, while in group 2, it was lower (LS mean ± SE, 2580 ± 951)
and later (24 h post-tulathromycin administration). However, these differences in tulathromycin
concentrations were not statistically significant. The change in the concentration vs. time profile
of tulathromycin observed in the middle lobe from animals challenged with LPS-Ec was not
reflected in PELF concentration results obtained in the same group (Chapter 5). The reasons for
this result are not clear.
During the last decade, the concept of tissue-directed pharmacokinetics has appeared
consistently in the literature referring to macrolides and lung tissue (1, 3, 6, 20, 21, 24, 25, 35,
48, 55). Tulathromycin has been found to accumulate in inflammatory cells such as neutrophils
and macrophages (12, 51), and it was demonstrated that the administration of LPS-Ec recruits
inflammatory cells (Chapter 3). In the present study, recruitment of cells was reflected in the cell
populations obtained in BAL fluid, mainly during the first 24 h post-dose administration (Fig.2).
Despite the given context, the concentrations of tulathromycin in PELF in group 2 were not
statistically different from those in group 1.
There were statistical differences in intracellular tulathromycin concentrations between
samples from group 1 and group 2, but the concentration vs. time profile of tulathromycin in both
groups is indistinguishable during the first 72 h post-dosing (Fig. 2). After that time, the
tulathromycin concentrations in group 2 decline at a remarkably lower rate than in group 1.
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Interestingly, evident differences in cell population proportions in BAL fluid samples between the
two groups were observed during the first 27 h post-LPS-Ec administration. However, statistical
differences in drug concentrations are determined by the concentration after 27 h post LPS-Ec.
During this period, the cell population observed in both treatment groups was represented by
epithelial cells. Contrary to what we were expecting, it was not possible to characterize the
samples into a unique cell population of either macrophages or neutrophils. The reason for this
result is unclear; the use of a fiberscope might explain these findings for group 1 but not for
group 2 (except for the 24 h sampling time). We were expecting to obtain mostly macrophages
(alveolar) in group 1 and neutrophils in the LPS-Ec-treated animals (group 2). Based on
previous studies, the intracellular concentration is estimated using a reference intracellular
volume calculated in a pellet of 106 macrophages or neutrophils. We set a minimum proportion
criterion (> 90% of either macrophages or neutrophils) in order to consider the reference
intracellular volume valid. None of the samples reached the minimum acceptance criterion.
Consequently, the results obtained only allow expression of the concentration of tulathromycin
in 106 cells rather than intracellular drug concentration in a specific cell population.
Despite wide acceptance that free drug concentrations dictate drug effects, we did not
evaluate if tulathromycin was unbound in BELF and PELF samples. This was not estimated due
to restrictions of techniques to harvest those samples. However, protein binding of tulathromycin
in ELF is expected to be negligible, since total protein concentration in ELF is relative low
(~10% of plasma concentration of protein) (26, 30, 49). Also, it is possible that the drug binds to
other components such as mucus, cells, and phospholipids. Consequently, we cannot assure
that the results obtained represent free extracellular drug concentrations.
Although the BAL fluid technique has been extensively used to describe drug
concentrations in the lung, some limitations have been recognized regarding the validity of drug
concentrations in PELF using this technique (12, 29, 59). One of the main drawbacks of this
technique is that cell-free PELF drug concentrations might be “contaminated” by the release of
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the intracellular drug, mainly from the highly loaded alveolar macrophages (31). An
overestimation of drug concentrations in PELF is strongly associated with the BAL fluid
technique and, at least for tulathromycin in cattle, might have a relevant impact on PELF
concentrations after 11 h post-administration of the drug (12, 29, 31). The magnitude of the
contamination in the samples is difficult to estimate; however, a short dwell time (~20s), the use
of pipettes, and immediate separation of the cell fraction from the sample after harvest of the
BAL fluid were implemented in order to minimize the potential confounding effect of the drug
concentrations in PELF (2, 31).
Different techniques have been used to describe the pulmonary drug distribution in
animals and humans, but their application is limited (9, 27, 52-54). Bronchoalveolar lavage fluid
has been extensively used in multiple species; however, pouring fluid into the airways certainly
modifies the sample site environment. This restricts the use of this technique to single or sparse
sampling schemes. Therefore, characterization of drug concentration profiles in PELF by the
use of BAL fluid may require a large number of animals to obtain acceptable and precise data.
Advantages and limitations of BMS probes are described elsewhere (Chapter 4), but in the
present study it was demonstrated that BMS probes can be used to describe the concentration
vs. time profile of tulathromycin in the intra-airway compartments. In addition, one of the most
remarkable advantages of this technique is that BMS probes can be introduced in multiple
sampling protocols, reducing the number of study animals and improving the precision of the
results. Additionally, it would eliminate and/or decrease the use of terminal studies to describe
the concentration vs. time profile of drugs, as required when using lung homogenate. Bronchial
micro-sampling probes represent a cost-effective technique that can be introduced in discovery
and preclinical pharmacokinetic studies for screening of candidate drugs that could be indicated
for treatment of respiratory conditions.
In conclusion, this is the first study that describes the disposition of tulathromycin in both
BELF and PELF after a single intramuscular dose of tulathromycin in pigs. The concentration-
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time profile of tulathromycin in airway fluid has been described using a novel technique. The use
of BMS probes might enhance the experimental design and maximize experimental resources
(number of animals, time, and cost). Pharmacokinetic parameters of tulathromycin were
estimated for BELF and PELF in healthy and LPS-Ec-challenged animals, and it was
demonstrated that tulathromycin not only distributed rapidly into the intra-airway compartments
(BELF and PELF) but also persisted in the airway lining fluid (at least 408 h) at relative high
concentrations in both healthy and LPS-Ec-challenged pigs.
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Appendix
Table 6.1. Summary of tulathromycin geometric mean drug concentrations (and 95% confidence limits) (ng/mL) in pulmonary and

Treatme
nt

6

T01

24

72

144

240

408

Group

Time
(h)

bronchial epithelial lining fluid from pigs following a single i.m. injection of tulathromycin at 2.5 mg/kg body weight.
Pulmonary epithelial lining
fluid
LS Mean† 95% CIs†

Range

Bronchial epithelial lining
fluid

Plasma&

Ratio

Raw Mean PELF/ BELF/ PELF/
Plasma Plasma BELF
149
29.6
2.69 11.0

LS Mean†

95% CIs†

Range

717

514-1000

268-1430

na

na

na

247

6.39

na

na

1

7890

2

1580

789-3170

1

4670

2330-9360 1550-28700

3570

2560-4970

2320-6420

61.9

75.4

57.7

1.30

2

2580

1220-5460 1000- 4290

3240

2260-4640

1950-4500

86.8

29.7

37.2

0.79

1

2270

1130-4540 1850- 3180

5040

3610-7030

3750-6380

22.5

101

224

0.45

2

1630

811-3260

424- 2840

na

na

na

19.8

82.3

na

na

1

566

282-1130

122-1610

3940

2830-5500

3060-4790

6.99

90.5

630

0.14

2

1070

507-2270

531-2440

na

na

na

7.67

140

na

na

1

495

247-994

256-1970

2940

2110-4100

2020-4250

1.82

271

1610

0.16

2

261

123-554

71.8-423

na

na

na

2.19

119

na

na

1

291

137-618

181-463

1680

1170-2410

1020-2610

1.36

213

1235

0.17

2

258

128-519

132-617

na

na

na

1.33

194

na

na

3940-15800 2410-67800
367- 5780

T02

T03

T04

T05

T06

†

Back transformed; NA, not applicable. &Plasma results were fully described in chapter 5 of the dissertation.
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Table 6.2. Summary of pharmacokinetic parameters for tulathromycin in PELF and BELF in pigs
treated i.m. with tulathromycin at 2.5 mg/kg
Matrices
PELF

Pharmacokinetic

BELF

parameter*

Group 1

Group 2

Group 1

HL_Lambda_z (h)

87.3

108

213

Tmax (h)

6.00

24.0

72.0

Cmax (ng/mL)

7890

2580

5040

Clast (ng/mL)

291

258

1680

AUClast(h x ng/mL)

522000

348000

1290000

AUCinf_obs (h x ng/mL)

559000

388000

1810000

46600000

39300000

223000000

MRTINF_pred (h)

107

146

328

AUC0-408 BELF:Plasma ratio¶

NA

NA

223

AUC0-408 PELF:Plasma ratio¶

90.6

62.8

NA

AUMClast(h x h x ng/mL)

*Dispersion data of the PK parameters are not presented because PK parameters were
estimated based on least square means derived from the naïve pooling from each sample point.
NA, not applicable. ¶Plasma drug concentration and AUC0-408 was described and estimated in
chapter 5 of the study
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Concentration (  g/mL)
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Plasma Dose Group 1
Plasma Dose Group 2

PELF Dose Group 1
PELF Dose Group 2
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Figure 6.1. Least squared means concentration (±SE) (ng/mL) of tulathromycin in PELF and
BELF, and mean concentration (±SE) in plasma from pigs treated i.m. with tulathromycin at 2.5
mg/kg((n=6) (except for group 1 in PEL F and BELF at 408h n=5 and group 2 in PEL F at 24
and 144 h (n=5)).
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17.5

12.5

Dose Group 1
Dose Group 2
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Concentration in 10 cell
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Figure 6.2. Least squared means concentration (±SE) (ng/mL) of tulathromycin in 106 cells
harvested by BAL fluid from pigs ((n=6) (except for group 1 at 408h, n=5 and group 2 at 24 and
144 h, n=5) treated i.m. with tulathromycin at 2.5 mg/kg.
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Chapter 7:

CONCLUSION

This dissertation evaluates the pulmonary pharmacokinetics of tulathromycin in mice and
pigs. Tulathromycin is widely used as part of the health management of swine and bovine
practices as metaphylactic and therapeutic for respiratory disease. One of the most relevant
pharmacokinetic features of tulathromycin is its capacity to accumulate extensively in lung
tissue after a single dose. The kinetics of the drug in lung tissue is characterized by a rapid rate
of accumulation but a slow rate of depletion from the organ. However, the amount of information
available about the pharmacokinetics of tulathromycin in lung tissue is scarce. The mechanism
(s) of accumulation of the drug in lung tissue is unknown and information about the kinetics of
the drug in target anatomical areas is limited. In pigs, there was only one study that evaluated
the pulmonary pharmacokinetics of tulathromycin. This study was based on a single
representative lung homogenate sample per animal. However, there was no information
available concerning the within organ distribution and pharmacokinetics of the drug in the intraairways compartment. However, unequal drug distribution within an organ may have important
therapeutic consequences.
Studies in this dissertation provide information about the pharmacokinetics of
tulathromycin at two different lung levels, middle and caudal lobe. Results indicate that
tulathromycin accumulates notably in lung tissue at different sections within the organ. The
concentration vs. time profile of the drug and pharmacokinetic parameters in middle and caudal
lobes were similar. This suggests that tulathromycin distributes homogenously within the lungs,
at least in the middle and caudal lobes.
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In general, pulmonary pharmacokinetic studies are done in healthy animals. However,
inflammation may change the disposition of drugs in tissues. Therefore, information generated
from healthy animals limits the applicability of the results. Information from healthy animals may
be valuable for drugs with metaphylactic claims but may be misleading for therapeutic claims.
In order to evaluate the potential impact of an inflammatory response on the
concentration vs. time profile of tulathromycin, animals were challenged with lipopolysaccharide
of Escherichia coli which triggers an acute inflammatory response. The first study was done in
mice followed by the study in pigs.
Tulathromycin was administered to neutropenic and neutrophilic mice. There were no
statistically significant differences in the concentration of tulathromycin in lung tissue and
plasma among healthy mice, neutropenic mice and neutrophilic mice challenged with LPS-Ec.
In addition, neutrophils may not have a positive influence on tulathromycin accumulation in lung
tissue and an acute inflammatory response may not explain the fast and extensive accumulation
and long persistence of tulathromycin in lung. Further research is necessary to elucidate if
inflammatory cells have a relevant role in the accumulation of the drug in lung tissue of animals
with respiratory disease. Multiple scenarios should be evaluated including acute and chronic
respiratory disease.
In

pigs

challenged

with

LPS-Ec,

statistically

significant

lower

tulathromycin

concentration were found at 6 and 72 h post-drug administration in the middle lobe and at 24
and 72 h post-drug administration in the caudal lobe. These lower concentrations influenced the
concentration vs. time profile of the drug in lung tissue from the middle and caudal lobe. Even
though the concentration vs. time profile of the drug in lung tissue changed, the drug still
distributed into lung tissue to a large extent. The distribution of the drug was rapid and persisted
at relatively high levels for 17 days post-tulathromycin administration (LT: plasma ratio > 300 at
17 days post-tulathromycin administration).
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The clinical significance of the change in the concentration vs. time profile in lung tissue
is unknown. The inflammatory model used in this dissertation was not compared to natural
occurring respiratory disease caused by usual target microorganisms. Therefore, results
obtained and conclusions made in this dissertation are not fully extrapolable to field conditions.
Further research is necessary in this area. Evaluation of the potential impact of natural occurring
respiratory disease on the concentration vs. time profile of the drug in lung compartments would
provide valuable information for the understanding of the factors affecting the clinical efficacy of
tulathromycin.
Drug concentration at the site of infection is linked to the efficacy profile of
antimicrobials. In respiratory conditions, the target tissue is the lung, in particular the
extracellular fluid, such as the epithelial lining fluid that covers the route of entry, and
colonization of microorganisms associated with pneumonia. Therefore, the accumulation and
concentration time profile of the drug in the intra-airways compartment represents relevant
information to understand the antimicrobial effect of the drug and may help to delineate dosage
regimes based on target microorganism susceptibilities.
As reported for lung tissue samples, results indicate that the tulathromycin
concentrations were notably high in the intra-airway compartment. The concentration of
tulathromycin in the pulmonary and bronchial epithelial lining fluid (PELF and BELF) far
exceeded plasma concentrations (ratio range 29.6-271 and 2.69-1610 for PELF:plasma and
BELF:plasma, respectively). Tulathromycin penetrated quickly into the airway compartment, but
was slowly eliminated. Therefore, the extraordinary clinical outcome of the drug after a single
administration may be explained not only by the magnitude of drug accumulation but also the
long persistence of the drug in the intra-airway compartments. Interestingly, the lower
concentrations observed in lung tissue at some sample points of LPS-challenged animals were
not reflected in PELF concentration.
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Fibrerscopically guide bronchial microsampling probes (BMSp) were used for the
assessment of the concentration-time profile of tulathromycin in BELF. This technique has not
previously been evaluated in veterinary species. We identified the limitations and advantages
for the use of this technique for the evaluation of the pharmacokinetics of drugs in BELF from
veterinary species. The limitations of BMSp are (i) it may not be possible to harvest unbound
drug and (ii) it is not possible to harvest BELF at all airways sections. In contrast to other
techniques, one of the most important advantages of BMSp, is that it makes possible to improve
the anatomical resolution of the samples. Bronchial micro-sampling probes permits to take
samples from potential infection sites in the intra- and extra-pulmonary airways.
Due to the anatomical location and function of the lung, it is experimentally difficult to
obtain relevant information to evaluate lung pharmacokinetic of the drugs. The studies done in
this dissertation indicate that the BMSp may represent a valuable tool to study the pulmonary
pharmacokinetics of drugs not only in pigs but also in other veterinary species. The use of
BMSp represents a cost-effective technique that enhances the experimental design and
maximizes experimental resources (number of animals, time, and cost).
This dissertation expands our understanding about the distribution of tulathromycin into
lungs. Studies in this dissertation are the first studies that evaluate the kinetics of the drug in
middle and caudal lobes and intra-airway compartments from healthy pigs and animals with an
acute pulmonary inflammatory response. This work provides the first evidence of the
pharmacokinetics of tulathromycin in lung tissue administered to neutropenic, normopenic and
neutrophilic mice. Finally, this dissertation introduces and evaluates an innovative technique for
the study of pulmonary pharmacokinetics of drugs in veterinary species.
Further research is necessary to define the mechanisms and factors involved in the
kinetics of tulathromycin in the lungs. Two additional pieces of information certainly may help to
unravel the unique pharmacokinetic profile of tulathromycin in lung tissue, namely (i) the
evaluation of the impact of chronic inflammation on the pulmonary pharmacokinetics of the drug,
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and (ii) the influence of the time of drug administration with respect to the pathological stage on
the concentration vs. time profile of the drug in the intra-airways compartment. Finally, research
emphasis should be put on the characterization of the unbound drug concentration at different
levels in the intra-airways compartment.
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